WO2022143740A1 - A3腺苷受体激动剂及其制备方法和用途 - Google Patents
A3腺苷受体激动剂及其制备方法和用途 Download PDFInfo
- Publication number
- WO2022143740A1 WO2022143740A1 PCT/CN2021/142384 CN2021142384W WO2022143740A1 WO 2022143740 A1 WO2022143740 A1 WO 2022143740A1 CN 2021142384 W CN2021142384 W CN 2021142384W WO 2022143740 A1 WO2022143740 A1 WO 2022143740A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carboxamide
- purin
- dihydroxy
- methyl
- tetrahydrofuran
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 15
- 229940122216 Adenosine A3 receptor agonist Drugs 0.000 title abstract 2
- 239000002593 adenosine A3 receptor agonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 355
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- -1 hydroxy, amino Chemical group 0.000 claims description 239
- 101150046889 ADORA3 gene Proteins 0.000 claims description 79
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 60
- 229910052736 halogen Inorganic materials 0.000 claims description 57
- 150000002367 halogens Chemical class 0.000 claims description 53
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 239000001257 hydrogen Substances 0.000 claims description 51
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 46
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 43
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 35
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 35
- 229910052805 deuterium Inorganic materials 0.000 claims description 35
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000004122 cyclic group Chemical group 0.000 claims description 30
- 150000002431 hydrogen Chemical class 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
- GXHAENUAJYZNOA-UHFFFAOYSA-N oxolane-2-carboxamide Chemical compound NC(=O)C1CCCO1 GXHAENUAJYZNOA-UHFFFAOYSA-N 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 21
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 18
- 239000000651 prodrug Substances 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 239000002207 metabolite Substances 0.000 claims description 16
- 125000003368 amide group Chemical group 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 14
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 14
- 230000000155 isotopic effect Effects 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229940122614 Adenosine receptor agonist Drugs 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 239000003379 purinergic P1 receptor agonist Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 5
- NOWQQVCJGZFZSN-PBQROFAYSA-N (2S,3S,4R,5R)-3,4-dihydroxy-N-methyl-5-[6-[(3-methylphenyl)methylamino]-2-(5-methylpyridin-3-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CC1=CC=CC(CNC2=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=NC(C3=CC(C)=CN=C3)=N2)=C1 NOWQQVCJGZFZSN-PBQROFAYSA-N 0.000 claims description 4
- KXEMEXZPZGXVPH-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-[(4-methoxypyridin-2-yl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=NC=CC(OC)=C3)=C2N=C1)=O KXEMEXZPZGXVPH-DDOIHHOZSA-N 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- JQPLPMTXYJUCDD-PFHKOEEOSA-N (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]oxolane-2-carbohydrazide Chemical compound NNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC=NC(NCC3=CC(I)=CC=C3)=C2N=C1)=O JQPLPMTXYJUCDD-PFHKOEEOSA-N 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- FTAPGYPNISFHGQ-SSHHRWTQSA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-(methylamino)-2-(5-methylpyridin-3-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(C)=CN=C3)=NC(NC)=C2N=C1)=O FTAPGYPNISFHGQ-SSHHRWTQSA-N 0.000 claims 2
- SQVUFOLRVQBFSH-CVXDAYKESA-N (2S,3S,4R,5R)-3,4-dihydroxy-5-[2-(5-methoxypyridin-3-yl)-6-(methylamino)purin-9-yl]-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(OC)=CN=C3)=NC(NC)=C2N=C1)=O SQVUFOLRVQBFSH-CVXDAYKESA-N 0.000 claims 1
- QZINYDUOCVHRJR-DDOIHHOZSA-N (2S,3S,4R,5R)-3,4-dihydroxy-5-[2-(5-methoxypyridin-3-yl)-6-[[6-(trifluoromethyl)pyridin-2-yl]methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(OC)=CN=C3)=NC(NCC3=NC(C(F)(F)F)=CC=C3)=C2N=C1)=O QZINYDUOCVHRJR-DDOIHHOZSA-N 0.000 claims 1
- IHZMNWQZKZYKTM-MOROJQBDSA-N (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N'-methyloxolane-2-carbohydrazide Chemical compound CNNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC=NC(NCC3=CC(I)=CC=C3)=C2N=C1)=O IHZMNWQZKZYKTM-MOROJQBDSA-N 0.000 claims 1
- ZTDQEGCVQBZBDT-MOROJQBDSA-N (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methoxyoxolane-2-carboxamide Chemical compound CONC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC=NC(NCC3=CC(I)=CC=C3)=C2N=C1)=O ZTDQEGCVQBZBDT-MOROJQBDSA-N 0.000 claims 1
- OCKIBZUQLYVLHN-PBQROFAYSA-N (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-methoxyphenyl)methylamino]-2-(5-methoxypyridin-3-yl)purin-9-yl]-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(OC)=CN=C3)=NC(NCC3=CC(OC)=CC=C3)=C2N=C1)=O OCKIBZUQLYVLHN-PBQROFAYSA-N 0.000 claims 1
- GVKOLYNETHRTSI-PBQROFAYSA-N (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-methoxyphenyl)methylamino]-2-(5-methylpyridin-3-yl)purin-9-yl]-N-methyloxolane-2-carboxamide Chemical compound CC1=CN=CC(C2=NC(NCC3=CC(OC)=CC=C3)=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=N2)=C1 GVKOLYNETHRTSI-PBQROFAYSA-N 0.000 claims 1
- XQOBDIFLWVUQNG-UAKAABGRSA-N (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-methoxyphenyl)methylamino]-2-pyridin-3-ylpurin-9-yl]-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=CN=C3)=NC(NCC3=CC(OC)=CC=C3)=C2N=C1)=O XQOBDIFLWVUQNG-UAKAABGRSA-N 0.000 claims 1
- NSRIZXCFNGTAOP-DDOIHHOZSA-N (2S,3S,4R,5R)-3,4-dihydroxy-N-methoxy-5-[6-(methylamino)-2-(5-phenoxypyridin-3-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CNC1=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NOC)=O)C2=NC(C2=CC(OC3=CC=CC=C3)=CN=C2)=N1 NSRIZXCFNGTAOP-DDOIHHOZSA-N 0.000 claims 1
- OTZZGCXWSADVRN-UAKAABGRSA-N (2S,3S,4R,5R)-3,4-dihydroxy-N-methoxy-5-[6-(methylamino)-2-(5-phenylmethoxypyridin-3-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CNC1=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NOC)=O)C2=NC(C2=CC(OCC3=CC=CC=C3)=CN=C2)=N1 OTZZGCXWSADVRN-UAKAABGRSA-N 0.000 claims 1
- YNIJEOAPGMGAAM-LDNFRZNASA-N (2S,3S,4R,5R)-3,4-dihydroxy-N-methoxy-5-[6-(methylamino)-2-(5-propan-2-yloxypyridin-3-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CC(C)OC1=CN=CC(C2=NC(NC)=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NOC)=O)C3=N2)=C1 YNIJEOAPGMGAAM-LDNFRZNASA-N 0.000 claims 1
- VDQRYWSTDOYDGH-DDOIHHOZSA-N (2S,3S,4R,5R)-3,4-dihydroxy-N-methyl-5-[2-(5-methylpyridin-3-yl)-6-(pyridin-2-ylmethylamino)purin-9-yl]oxolane-2-carboxamide Chemical compound CC1=CN=CC(C2=NC(NCC3=NC=CC=C3)=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=N2)=C1 VDQRYWSTDOYDGH-DDOIHHOZSA-N 0.000 claims 1
- LNLOVRZTSGEICZ-UAKAABGRSA-N (2S,3S,4R,5R)-3,4-dihydroxy-N-methyl-5-[2-(5-methylpyridin-3-yl)-6-[(6-methylpyridin-2-yl)methylamino]purin-9-yl]oxolane-2-carboxamide Chemical compound CC1=CN=CC(C2=NC(NCC3=NC(C)=CC=C3)=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=N2)=C1 LNLOVRZTSGEICZ-UAKAABGRSA-N 0.000 claims 1
- CBVBJRHRTWTPKI-DDOIHHOZSA-N (2S,3S,4R,5R)-3,4-dihydroxy-N-methyl-5-[2-pyridin-3-yl-6-[[3-(trifluoromethyl)phenyl]methylamino]purin-9-yl]oxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=CN=C3)=NC(NCC3=CC(C(F)(F)F)=CC=C3)=C2N=C1)=O CBVBJRHRTWTPKI-DDOIHHOZSA-N 0.000 claims 1
- UXZDLSFHEPRWJN-DDOIHHOZSA-N (2S,3S,4R,5R)-3,4-dihydroxy-N-methyl-5-[6-[(4-methylpyridin-2-yl)methylamino]-2-pyridin-3-ylpurin-9-yl]oxolane-2-carboxamide Chemical compound CC1=CC(CNC2=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=NC(C3=CC=CN=C3)=N2)=NC=C1 UXZDLSFHEPRWJN-DDOIHHOZSA-N 0.000 claims 1
- SKEZUBNBAOPRPL-CVXDAYKESA-N (2S,3S,4R,5R)-5-[2-(1,3-dimethylpyrazol-4-yl)-6-(methylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CN(C)N=C3C)=NC(NC)=C2N=C1)=O SKEZUBNBAOPRPL-CVXDAYKESA-N 0.000 claims 1
- XYMVTIORTYKCGJ-CVXDAYKESA-N (2S,3S,4R,5R)-5-[2-(1,5-dimethylpyrazol-4-yl)-6-(methylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=C(C)N(C)N=C3)=NC(NC)=C2N=C1)=O XYMVTIORTYKCGJ-CVXDAYKESA-N 0.000 claims 1
- BAHLVBQUUTURMG-QUIZZNFMSA-N (2S,3S,4R,5R)-5-[2-(2-chloro-3-methylimidazol-4-yl)-6-(methylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(N3C)=CN=C3Cl)=NC(NC)=C2N=C1)=O BAHLVBQUUTURMG-QUIZZNFMSA-N 0.000 claims 1
- GUMZMBVQKQZTIG-VZVWNTEVSA-N (2S,3S,4R,5R)-5-[2-(2-chlorothiophen-3-yl)-6-(methylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C=CS3)=C3Cl)=NC(NC)=C2N=C1)=O GUMZMBVQKQZTIG-VZVWNTEVSA-N 0.000 claims 1
- DJMYDJUVGGVCGY-CVXDAYKESA-N (2S,3S,4R,5R)-5-[2-(3,5-dimethyl-1H-pyrazol-4-yl)-6-(methylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=C(C)NN=C3C)=NC(NC)=C2N=C1)=O DJMYDJUVGGVCGY-CVXDAYKESA-N 0.000 claims 1
- GACRDOMNRSNSRO-PBQROFAYSA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-(2-phenylethylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCCC3=CC=CC=C3)=C2N=C1)=O GACRDOMNRSNSRO-PBQROFAYSA-N 0.000 claims 1
- FRXJVAAWVLRFOK-HBGPKNEHSA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-(methylamino)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NC)=C2N=C1)=O FRXJVAAWVLRFOK-HBGPKNEHSA-N 0.000 claims 1
- JXDAUOGQLRFHCG-CVXDAYKESA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-(methylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NC)=C2N=C1)=O JXDAUOGQLRFHCG-CVXDAYKESA-N 0.000 claims 1
- RKNUFMBPHYLWJR-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-[(3,4-difluorophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC(C=C3)=CC(F)=C3F)=C2N=C1)=O RKNUFMBPHYLWJR-DDOIHHOZSA-N 0.000 claims 1
- NLOYAHGSYMKGKW-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-[(3-fluorophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-(2,2,2-trifluoroethyl)oxolane-2-carboxamide Chemical compound O[C@@H]([C@H]1O)[C@@H](C(NCC(F)(F)F)=O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(F)=CC=C3)=C2N=C1 NLOYAHGSYMKGKW-DDOIHHOZSA-N 0.000 claims 1
- PZOBRHDTDRBKAE-UAKAABGRSA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-[(3-fluorophenyl)methylamino]purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(F)=CC=C3)=C2N=C1)=O PZOBRHDTDRBKAE-UAKAABGRSA-N 0.000 claims 1
- AKBQEJRWXMRJCV-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-(2,2,2-trifluoroethyl)oxolane-2-carboxamide Chemical compound O[C@@H]([C@H]1O)[C@@H](C(NCC(F)(F)F)=O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(I)=CC=C3)=C2N=C1 AKBQEJRWXMRJCV-DDOIHHOZSA-N 0.000 claims 1
- LRQSNYYHGHBGLR-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(I)=CC=C3)=C2N=C1)=O LRQSNYYHGHBGLR-DDOIHHOZSA-N 0.000 claims 1
- IJWGDWRHYYLTIN-UAKAABGRSA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-[(3-iodophenyl)methylamino]purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(I)=CC=C3)=C2N=C1)=O IJWGDWRHYYLTIN-UAKAABGRSA-N 0.000 claims 1
- NFZUFJQGRFRTNB-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-[(4-methylpyridin-2-yl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC1=CC(CNC2=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=NC(C3=CC(Cl)=CN=C3)=N2)=NC=C1 NFZUFJQGRFRTNB-DDOIHHOZSA-N 0.000 claims 1
- KTIWTRXRQSSQFV-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[2-(5-chloropyridin-3-yl)-6-[[3-(trifluoromethyl)phenyl]methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(C(F)(F)F)=CC=C3)=C2N=C1)=O KTIWTRXRQSSQFV-DDOIHHOZSA-N 0.000 claims 1
- KKPRPEQSUMPQQR-CVXDAYKESA-N (2S,3S,4R,5R)-5-[2-(5-cyanothiophen-2-yl)-6-(methylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=C(C#N)S3)=NC(NC)=C2N=C1)=O KKPRPEQSUMPQQR-CVXDAYKESA-N 0.000 claims 1
- NWWRBBPDTKKNMP-HBGPKNEHSA-N (2S,3S,4R,5R)-5-[2-(5-fluoropyridin-3-yl)-6-(methylamino)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(F)=CN=C3)=NC(NC)=C2N=C1)=O NWWRBBPDTKKNMP-HBGPKNEHSA-N 0.000 claims 1
- MVLYKPWDWUAJIE-UAKAABGRSA-N (2S,3S,4R,5R)-5-[2-(5-fluoropyridin-3-yl)-6-[(3-methoxyphenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(F)=CN=C3)=NC(NCC3=CC(OC)=CC=C3)=C2N=C1)=O MVLYKPWDWUAJIE-UAKAABGRSA-N 0.000 claims 1
- HHJFTCFNSSUTNV-UAKAABGRSA-N (2S,3S,4R,5R)-5-[2-(5-fluoropyridin-3-yl)-6-[(3-methylphenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC1=CC=CC(CNC2=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=NC(C3=CC(F)=CN=C3)=N2)=C1 HHJFTCFNSSUTNV-UAKAABGRSA-N 0.000 claims 1
- GMQQGNSKZWFDLX-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[2-(5-fluoropyridin-3-yl)-6-[(4-methylpyridin-2-yl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC1=CC(CNC2=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=NC(C3=CC(F)=CN=C3)=N2)=NC=C1 GMQQGNSKZWFDLX-DDOIHHOZSA-N 0.000 claims 1
- UJMKPQWBIJUNDC-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[2-(5-fluoropyridin-3-yl)-6-[[3-(trifluoromethyl)phenyl]methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(F)=CN=C3)=NC(NCC3=CC(C(F)(F)F)=CC=C3)=C2N=C1)=O UJMKPQWBIJUNDC-DDOIHHOZSA-N 0.000 claims 1
- AJPHUWRRTPAJGT-KSVNGYGVSA-N (2S,3S,4R,5R)-5-[2-benzyl-6-(methylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(CC3=CC=CC=C3)=NC(NC)=C2N=C1)=O AJPHUWRRTPAJGT-KSVNGYGVSA-N 0.000 claims 1
- OSJFVFKHBDCCSL-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(1-methylpyrrol-2-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=CN3C)=NC(NCC3=CC=CC=C3)=C2N=C1)=O OSJFVFKHBDCCSL-DDOIHHOZSA-N 0.000 claims 1
- YENWPOYBLNUCOS-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(2,3-difluorophenyl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C=CC=C3F)=C3F)=NC(NCC3=CC=CC=C3)=C2N=C1)=O YENWPOYBLNUCOS-UAKAABGRSA-N 0.000 claims 1
- MDVOAZDPMDSBPW-PBQROFAYSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(2-methoxyphenyl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C=CC=C3)=C3OC)=NC(NCC3=CC=CC=C3)=C2N=C1)=O MDVOAZDPMDSBPW-PBQROFAYSA-N 0.000 claims 1
- SNWGVUTZYDEOMK-PBQROFAYSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(2-methylphenyl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC(C=CC=C1)=C1C1=NC(NCC2=CC=CC=C2)=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NC)=O)C2=N1 SNWGVUTZYDEOMK-PBQROFAYSA-N 0.000 claims 1
- SJRDUEWCQQHAGD-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(2-methylpyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC1=NC=CC=C1C1=NC(NCC2=CC=CC=C2)=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NC)=O)C2=N1 SJRDUEWCQQHAGD-UAKAABGRSA-N 0.000 claims 1
- WHDFRHJVEDIDGN-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(3,4-difluorophenyl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C=C3)=CC(F)=C3F)=NC(NCC3=CC=CC=C3)=C2N=C1)=O WHDFRHJVEDIDGN-UAKAABGRSA-N 0.000 claims 1
- KZXXLCQAXPJGHT-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(3,5-difluorophenyl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(F)=CC(F)=C3)=NC(NCC3=CC=CC=C3)=C2N=C1)=O KZXXLCQAXPJGHT-UAKAABGRSA-N 0.000 claims 1
- KYLXMTIRWOCRDW-PBQROFAYSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(3-methoxyphenyl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(OC)=CC=C3)=NC(NCC3=CC=CC=C3)=C2N=C1)=O KYLXMTIRWOCRDW-PBQROFAYSA-N 0.000 claims 1
- DZXCFZSKMQLZMN-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(3-methylpyridin-4-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC(C=NC=C1)=C1C1=NC(NCC2=CC=CC=C2)=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NC)=O)C2=N1 DZXCFZSKMQLZMN-UAKAABGRSA-N 0.000 claims 1
- OJGURQOXPUHSHJ-PBQROFAYSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(4-methoxyphenyl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C=C3)=CC=C3OC)=NC(NCC3=CC=CC=C3)=C2N=C1)=O OJGURQOXPUHSHJ-PBQROFAYSA-N 0.000 claims 1
- BRLDBUBXOWXJDV-PBQROFAYSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(4-methylphenyl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC(C=C1)=CC=C1C1=NC(NCC2=CC=CC=C2)=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NC)=O)C2=N1 BRLDBUBXOWXJDV-PBQROFAYSA-N 0.000 claims 1
- GIMKVCYOUHMQMV-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(4-methylpyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC(C=CN=C1)=C1C1=NC(NCC2=CC=CC=C2)=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NC)=O)C2=N1 GIMKVCYOUHMQMV-UAKAABGRSA-N 0.000 claims 1
- HXFRMLVBMVFHEV-HNFJUSDZSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(4-pyridin-3-ylphenyl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C=C3)=CC=C3C3=CC=CN=C3)=NC(NCC3=CC=CC=C3)=C2N=C1)=O HXFRMLVBMVFHEV-HNFJUSDZSA-N 0.000 claims 1
- MDOJMFNLRQBUNP-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(5-chloropyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-(2,2,2-trifluoroethyl)oxolane-2-carboxamide Chemical compound O[C@@H]([C@H]1O)[C@@H](C(NCC(F)(F)F)=O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC=CC=C3)=C2N=C1 MDOJMFNLRQBUNP-DDOIHHOZSA-N 0.000 claims 1
- MCWDFFFQZGTVEK-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(5-chloropyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC=CC=C3)=C2N=C1)=O MCWDFFFQZGTVEK-DDOIHHOZSA-N 0.000 claims 1
- KQUNRRNDUKWPMY-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(5-chloropyridin-3-yl)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC=CC=C3)=C2N=C1)=O KQUNRRNDUKWPMY-UAKAABGRSA-N 0.000 claims 1
- YAHTWCLQUOACTO-PBQROFAYSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(5-ethoxypyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CCOC1=CN=CC(C2=NC(NCC3=CC=CC=C3)=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=N2)=C1 YAHTWCLQUOACTO-PBQROFAYSA-N 0.000 claims 1
- SPXPGAMTSZZBLJ-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(5-fluoropyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(F)=CN=C3)=NC(NCC3=CC=CC=C3)=C2N=C1)=O SPXPGAMTSZZBLJ-DDOIHHOZSA-N 0.000 claims 1
- NYWQXHQCBNNIGB-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(5-methoxypyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(OC)=CN=C3)=NC(NCC3=CC=CC=C3)=C2N=C1)=O NYWQXHQCBNNIGB-UAKAABGRSA-N 0.000 claims 1
- QBLBCIHWPTXIER-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(5-methylpyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC1=CN=CC(C2=NC(NCC3=CC=CC=C3)=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=N2)=C1 QBLBCIHWPTXIER-UAKAABGRSA-N 0.000 claims 1
- SZQIZOTVZJXEGN-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(5-nitropyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC([N+]([O-])=O)=CN=C3)=NC(NCC3=CC=CC=C3)=C2N=C1)=O SZQIZOTVZJXEGN-DDOIHHOZSA-N 0.000 claims 1
- ILFFXFNWMCFVDX-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-(6-methylpyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC(N=C1)=CC=C1C1=NC(NCC2=CC=CC=C2)=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NC)=O)C2=N1 ILFFXFNWMCFVDX-UAKAABGRSA-N 0.000 claims 1
- MGVNLLZMORWZFA-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-[2-(trifluoromethoxy)phenyl]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C=CC=C3)=C3OC(F)(F)F)=NC(NCC3=CC=CC=C3)=C2N=C1)=O MGVNLLZMORWZFA-UAKAABGRSA-N 0.000 claims 1
- XLAGXNYHFYODFD-PBQROFAYSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-[3-(methylamino)phenyl]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(NC)=CC=C3)=NC(NCC3=CC=CC=C3)=C2N=C1)=O XLAGXNYHFYODFD-PBQROFAYSA-N 0.000 claims 1
- OMGBXWAYLORTFG-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-[3-(trifluoromethoxy)phenyl]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(OC(F)(F)F)=CC=C3)=NC(NCC3=CC=CC=C3)=C2N=C1)=O OMGBXWAYLORTFG-UAKAABGRSA-N 0.000 claims 1
- IHHSIDLPAVIRHG-JLFWUPFSSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-[4-(2-methoxyethoxy)phenyl]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C=C3)=CC=C3OCCOC)=NC(NCC3=CC=CC=C3)=C2N=C1)=O IHHSIDLPAVIRHG-JLFWUPFSSA-N 0.000 claims 1
- NTVGLIFNLDQLGV-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-[4-(trifluoromethoxy)phenyl]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C=C3)=CC=C3OC(F)(F)F)=NC(NCC3=CC=CC=C3)=C2N=C1)=O NTVGLIFNLDQLGV-UAKAABGRSA-N 0.000 claims 1
- VCBCJICDKLVZFC-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-[5-(methylamino)pyridin-3-yl]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(NC)=CN=C3)=NC(NCC3=CC=CC=C3)=C2N=C1)=O VCBCJICDKLVZFC-UAKAABGRSA-N 0.000 claims 1
- BGDBKEWKUUCQBP-KKPNIWNPSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-[5-(propan-2-ylamino)pyridin-3-yl]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC(C)NC1=CN=CC(C2=NC(NCC3=CC=CC=C3)=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=N2)=C1 BGDBKEWKUUCQBP-KKPNIWNPSA-N 0.000 claims 1
- AEQMNWWXYQBYHX-KSVNGYGVSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-ethylpurin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CCC1=NC(NCC2=CC=CC=C2)=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NC)=O)C2=N1 AEQMNWWXYQBYHX-KSVNGYGVSA-N 0.000 claims 1
- MZEJXBSSKPQSQM-GRXQJBFDSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-ethylpurin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCC1=NC(NCC2=CC=CC=C2)=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NCC)=O)C2=N1 MZEJXBSSKPQSQM-GRXQJBFDSA-N 0.000 claims 1
- PFHVNLKKZNJBHS-KGWSRGFLSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-propan-2-ylpurin-9-yl]-3,4-dihydroxy-N-(2,2,2-trifluoroethyl)oxolane-2-carboxamide Chemical compound CC(C)C1=NC(NCC2=CC=CC=C2)=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NCC(F)(F)F)=O)C2=N1 PFHVNLKKZNJBHS-KGWSRGFLSA-N 0.000 claims 1
- JHBDQCYFYDNWDX-KGWSRGFLSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-propan-2-ylpurin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC(C)C1=NC(NCC2=CC=CC=C2)=C2N=CN([C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(NC)=O)C2=N1 JHBDQCYFYDNWDX-KGWSRGFLSA-N 0.000 claims 1
- QTLOPZHXVXMQEY-DVSDUFGPSA-N (2S,3S,4R,5R)-5-[6-(benzylamino)-2-propan-2-ylpurin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C)C)=NC(NCC3=CC=CC=C3)=C2N=C1)=O QTLOPZHXVXMQEY-DVSDUFGPSA-N 0.000 claims 1
- ZWWWMFUALDYXOQ-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-[(2-chloro-5-methylphenyl)methylamino]-2-(5-chloropyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC(C=C1)=CC(CNC2=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=NC(C3=CC(Cl)=CN=C3)=N2)=C1Cl ZWWWMFUALDYXOQ-UAKAABGRSA-N 0.000 claims 1
- HKPHQSVQXRUTRN-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-[(2-fluoro-5-methylphenyl)methylamino]-2-(5-fluoropyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC(C=C1)=CC(CNC2=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=NC(C3=CC(F)=CN=C3)=N2)=C1F HKPHQSVQXRUTRN-UAKAABGRSA-N 0.000 claims 1
- XMISSJKSQPZNQY-PBQROFAYSA-N (2S,3S,4R,5R)-5-[6-[(2-fluoro-5-methylphenyl)methylamino]-2-(5-methylpyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC(C=C1)=CC(CNC2=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=NC(C3=CC(C)=CN=C3)=N2)=C1F XMISSJKSQPZNQY-PBQROFAYSA-N 0.000 claims 1
- XKMHXFIIXRXLAE-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-[(2-fluoro-5-methylphenyl)methylamino]-2-pyridin-3-ylpurin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CC(C=C1)=CC(CNC2=C3N=CN([C@@H]([C@@H]([C@@H]4O)O)O[C@@H]4C(NC)=O)C3=NC(C3=CC=CN=C3)=N2)=C1F XKMHXFIIXRXLAE-UAKAABGRSA-N 0.000 claims 1
- DXPRUICHWAWKMY-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-[(3-bromophenyl)methylamino]-2-(5-chloropyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-(2,2,2-trifluoroethyl)oxolane-2-carboxamide Chemical compound O[C@@H]([C@H]1O)[C@@H](C(NCC(F)(F)F)=O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(Br)=CC=C3)=C2N=C1 DXPRUICHWAWKMY-DDOIHHOZSA-N 0.000 claims 1
- DJEUXALJYADQQH-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-[(3-bromophenyl)methylamino]-2-(5-chloropyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(Br)=CC=C3)=C2N=C1)=O DJEUXALJYADQQH-DDOIHHOZSA-N 0.000 claims 1
- AQSSMKYJVGULNI-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-[(3-bromophenyl)methylamino]-2-(5-chloropyridin-3-yl)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(Br)=CC=C3)=C2N=C1)=O AQSSMKYJVGULNI-UAKAABGRSA-N 0.000 claims 1
- ZBPFDCOBDPJEKR-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-[(3-chlorophenyl)methylamino]-2-(5-chloropyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-(2,2,2-trifluoroethyl)oxolane-2-carboxamide Chemical compound O[C@@H]([C@H]1O)[C@@H](C(NCC(F)(F)F)=O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(Cl)=CC=C3)=C2N=C1 ZBPFDCOBDPJEKR-DDOIHHOZSA-N 0.000 claims 1
- JWOLJVWPIROGSJ-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-[(3-chlorophenyl)methylamino]-2-(5-chloropyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(Cl)=CC=C3)=C2N=C1)=O JWOLJVWPIROGSJ-DDOIHHOZSA-N 0.000 claims 1
- ZBNOMIHKICGHBA-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-[(3-chlorophenyl)methylamino]-2-(5-chloropyridin-3-yl)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(Cl)=CN=C3)=NC(NCC3=CC(Cl)=CC=C3)=C2N=C1)=O ZBNOMIHKICGHBA-UAKAABGRSA-N 0.000 claims 1
- HIHCVJIZIATQRU-UAKAABGRSA-N (2S,3S,4R,5R)-5-[6-[(3-chlorophenyl)methylamino]-2-(5-methoxypyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(OC)=CN=C3)=NC(NCC3=CC(Cl)=CC=C3)=C2N=C1)=O HIHCVJIZIATQRU-UAKAABGRSA-N 0.000 claims 1
- WZHBRYXDJIOMOE-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-[(3-chlorophenyl)methylamino]-2-pyridin-3-ylpurin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=CN=C3)=NC(NCC3=CC(Cl)=CC=C3)=C2N=C1)=O WZHBRYXDJIOMOE-DDOIHHOZSA-N 0.000 claims 1
- WMVLNIPEZRHVKC-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-[(4-chloropyridin-2-yl)methylamino]-2-(5-methoxypyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(OC)=CN=C3)=NC(NCC3=NC=CC(Cl)=C3)=C2N=C1)=O WMVLNIPEZRHVKC-DDOIHHOZSA-N 0.000 claims 1
- TUORBTREISFZTR-DVSDUFGPSA-N (2S,3S,4R,5R)-5-[6-[(4-chloropyridin-2-yl)methylamino]-2-pyridin-3-ylpurin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=CN=C3)=NC(NCC3=NC=CC(Cl)=C3)=C2N=C1)=O TUORBTREISFZTR-DVSDUFGPSA-N 0.000 claims 1
- LYZYNMJGBZOOOE-DDOIHHOZSA-N (2S,3S,4R,5R)-5-[6-[(6-chloropyridin-2-yl)methylamino]-2-(5-methoxypyridin-3-yl)purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide Chemical compound CNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(OC)=CN=C3)=NC(NCC3=NC(Cl)=CC=C3)=C2N=C1)=O LYZYNMJGBZOOOE-DDOIHHOZSA-N 0.000 claims 1
- UBAXBHSJERRMFZ-PFHKOEEOSA-N (2S,3S,4R,5R)-N,3,4-trihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]oxolane-2-carboxamide Chemical compound O[C@@H]([C@H]1O)[C@@H](C(NO)=O)O[C@H]1N1C2=NC=NC(NCC3=CC(I)=CC=C3)=C2N=C1 UBAXBHSJERRMFZ-PFHKOEEOSA-N 0.000 claims 1
- CTDMRJXOLMVCLH-XUOCYBMCSA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[2-(2-methoxypyridin-3-yl)-6-(methylamino)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=CN=C3OC)=NC(NC)=C2N=C1)=O CTDMRJXOLMVCLH-XUOCYBMCSA-N 0.000 claims 1
- OTZOWTOZNKSUQG-SSHHRWTQSA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[2-(4-methoxypyridin-3-yl)-6-(methylamino)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C=NC=C3)=C3OC)=NC(NC)=C2N=C1)=O OTZOWTOZNKSUQG-SSHHRWTQSA-N 0.000 claims 1
- GYTYSVNQIYEFNV-SSHHRWTQSA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[2-(5-methoxypyridin-3-yl)-6-(methylamino)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(OC)=CN=C3)=NC(NC)=C2N=C1)=O GYTYSVNQIYEFNV-SSHHRWTQSA-N 0.000 claims 1
- FKVJVTLDGCYMHL-SSHHRWTQSA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[2-(6-methoxypyridin-3-yl)-6-(methylamino)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C(C=N3)=CC=C3OC)=NC(NC)=C2N=C1)=O FKVJVTLDGCYMHL-SSHHRWTQSA-N 0.000 claims 1
- HIKVGFSSOIPMIS-DDOIHHOZSA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-(methylamino)-2-(1-methyl-3-phenylpyrazol-4-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CN(C)N=C3C3=CC=CC=C3)=NC(NC)=C2N=C1)=O HIKVGFSSOIPMIS-DDOIHHOZSA-N 0.000 claims 1
- RGXUTTXFGDQVHS-HBGPKNEHSA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-(methylamino)-2-(1-methylimidazol-4-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CN(C)C=N3)=NC(NC)=C2N=C1)=O RGXUTTXFGDQVHS-HBGPKNEHSA-N 0.000 claims 1
- LMDSUOJCIQWWTQ-HBGPKNEHSA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-(methylamino)-2-(1-methylpyrazol-4-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CN(C)N=C3)=NC(NC)=C2N=C1)=O LMDSUOJCIQWWTQ-HBGPKNEHSA-N 0.000 claims 1
- KYNZZHJPDCBAKB-CVXDAYKESA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-(methylamino)-2-(1-methylpyrrol-2-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=CN3C)=NC(NC)=C2N=C1)=O KYNZZHJPDCBAKB-CVXDAYKESA-N 0.000 claims 1
- NNNSQHZATRKMDQ-CVXDAYKESA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-(methylamino)-2-(1-methylpyrrol-3-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CN(C)C=C3)=NC(NC)=C2N=C1)=O NNNSQHZATRKMDQ-CVXDAYKESA-N 0.000 claims 1
- DCUNILUIFIUDKQ-CVXDAYKESA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-(methylamino)-2-(4-methylthiophen-2-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(C)=CS3)=NC(NC)=C2N=C1)=O DCUNILUIFIUDKQ-CVXDAYKESA-N 0.000 claims 1
- OZGUUIGNBJSQBW-CVXDAYKESA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-(methylamino)-2-(5-methylfuran-2-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=C(C)O3)=NC(NC)=C2N=C1)=O OZGUUIGNBJSQBW-CVXDAYKESA-N 0.000 claims 1
- QLYQPTOVTIEKRW-CVXDAYKESA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-(methylamino)-2-(5-methylthiophen-2-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=C(C)S3)=NC(NC)=C2N=C1)=O QLYQPTOVTIEKRW-CVXDAYKESA-N 0.000 claims 1
- IWRSQDJNWBBVRP-DDOIHHOZSA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-(methylamino)-2-(5-phenylthiophen-2-yl)purin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=C(C4=CC=CC=C4)S3)=NC(NC)=C2N=C1)=O IWRSQDJNWBBVRP-DDOIHHOZSA-N 0.000 claims 1
- YKQUYHLBGFUYBF-CVXDAYKESA-N (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-(methylamino)-2-pyridin-3-ylpurin-9-yl]oxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=CN=C3)=NC(NC)=C2N=C1)=O YKQUYHLBGFUYBF-CVXDAYKESA-N 0.000 claims 1
- ZGTSQKDWEXYIJA-CVXDAYKESA-N (2S,3S,4R,5R)-N-ethyl-5-[2-(5-fluoropyridin-3-yl)-6-(methylamino)purin-9-yl]-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC(F)=CN=C3)=NC(NC)=C2N=C1)=O ZGTSQKDWEXYIJA-CVXDAYKESA-N 0.000 claims 1
- BWTBDIKLISTFQR-HBGPKNEHSA-N (2S,3S,4R,5R)-N-ethyl-5-[2-(furan-2-yl)-6-(methylamino)purin-9-yl]-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=CC=CO3)=NC(NC)=C2N=C1)=O BWTBDIKLISTFQR-HBGPKNEHSA-N 0.000 claims 1
- VNTLKAWTFGCGGH-HBGPKNEHSA-N (2S,3S,4R,5R)-N-ethyl-5-[2-(furan-3-yl)-6-(methylamino)purin-9-yl]-3,4-dihydroxyoxolane-2-carboxamide Chemical compound CCNC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC(C3=COC=C3)=NC(NC)=C2N=C1)=O VNTLKAWTFGCGGH-HBGPKNEHSA-N 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 abstract description 26
- 238000000034 method Methods 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 18
- 238000011282 treatment Methods 0.000 abstract description 17
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 9
- 230000004224 protection Effects 0.000 abstract description 6
- 230000002107 myocardial effect Effects 0.000 abstract description 5
- 208000030533 eye disease Diseases 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 230000002924 anti-infective effect Effects 0.000 abstract description 2
- 230000004112 neuroprotection Effects 0.000 abstract description 2
- 102000008161 Adenosine A3 Receptor Human genes 0.000 abstract 1
- 108010060261 Adenosine A3 Receptor Proteins 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 129
- 238000006243 chemical reaction Methods 0.000 description 109
- 230000015572 biosynthetic process Effects 0.000 description 87
- 238000003786 synthesis reaction Methods 0.000 description 85
- 239000007787 solid Substances 0.000 description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- 238000005481 NMR spectroscopy Methods 0.000 description 53
- 239000012044 organic layer Substances 0.000 description 48
- 235000019439 ethyl acetate Nutrition 0.000 description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000012043 crude product Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 35
- 230000002829 reductive effect Effects 0.000 description 29
- 125000006239 protecting group Chemical group 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 239000002904 solvent Substances 0.000 description 26
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 22
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
- 230000004913 activation Effects 0.000 description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 16
- 229920001223 polyethylene glycol Polymers 0.000 description 16
- 238000001514 detection method Methods 0.000 description 13
- 238000010791 quenching Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 11
- 229960005305 adenosine Drugs 0.000 description 11
- 229910052801 chlorine Inorganic materials 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 238000010511 deprotection reaction Methods 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 108050000203 Adenosine receptors Proteins 0.000 description 8
- 102000009346 Adenosine receptors Human genes 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 125000001309 chloro group Chemical group Cl* 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012131 assay buffer Substances 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 7
- 238000006482 condensation reaction Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229910052740 iodine Chemical group 0.000 description 7
- 239000011630 iodine Chemical group 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- ZPDIRKNRUWXYLJ-UHFFFAOYSA-N 2,2-dimethyloxolane Chemical compound CC1(C)CCCO1 ZPDIRKNRUWXYLJ-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000005907 alkyl ester group Chemical group 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 102100036006 Adenosine receptor A3 Human genes 0.000 description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
- 101000783645 Homo sapiens Adenosine receptor A3 Proteins 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical class [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 4
- MKDUUUBNJFUNJR-UHFFFAOYSA-N n-methyloxolane-2-carboxamide Chemical compound CNC(=O)C1CCCO1 MKDUUUBNJFUNJR-UHFFFAOYSA-N 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 3
- 229960003081 probenecid Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- COLOHWPRNRVWPI-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound [CH2]C(F)(F)F COLOHWPRNRVWPI-UHFFFAOYSA-N 0.000 description 2
- RVWUHFFPEOKYLB-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1(C)CCCC(C)(C)[NH+]1[O-] RVWUHFFPEOKYLB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NNWFSRBWMOZDAK-UHFFFAOYSA-N 2-[2-(carboxymethyl)-3-iodophenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(I)=C1CC(O)=O NNWFSRBWMOZDAK-UHFFFAOYSA-N 0.000 description 2
- RPVDWHOGJOXVJK-UHFFFAOYSA-N 2-ethyl-3,7-dihydropurin-6-one Chemical compound O=C1NC(CC)=NC2=C1NC=N2 RPVDWHOGJOXVJK-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 101150051188 Adora2a gene Proteins 0.000 description 2
- 101150078577 Adora2b gene Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- UHBGYFCCKRAEHA-UHFFFAOYSA-N P-toluamide Chemical compound CC1=CC=C(C(N)=O)C=C1 UHBGYFCCKRAEHA-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000013262 cAMP assay Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 230000003293 cardioprotective effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- BFXLJWUGRPGMFU-UHFFFAOYSA-N dipropoxyphosphinothioyl n,n-diethylcarbamodithioate;sulfane Chemical compound S.CCCOP(=S)(OCCC)SC(=S)N(CC)CC BFXLJWUGRPGMFU-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- ZHNUHDYFZUAESO-AYQNKDEESA-N n,n,1-trideuterioformamide Chemical compound [2H]N([2H])C([2H])=O ZHNUHDYFZUAESO-AYQNKDEESA-N 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- BFEJWDAKSZKAKR-PKIKSRDPSA-N (2S,3S,4R,5S)-3,4,5-triacetyloxyoxolane-2-carboxylic acid Chemical compound CC(=O)O[C@@H]1O[C@@H]([C@@H](OC(C)=O)[C@H]1OC(C)=O)C(O)=O BFEJWDAKSZKAKR-PKIKSRDPSA-N 0.000 description 1
- XHRJGHCQQPETRH-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(Cl)=C2N=C1 XHRJGHCQQPETRH-KQYNXXCUSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- NJXYBTMCTZAUEE-UHFFFAOYSA-N (5-chloropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CN=CC(Cl)=C1 NJXYBTMCTZAUEE-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- RQTNGBCKFZJCGA-UHFFFAOYSA-N 2-chloro-N-[(3-methylphenyl)methyl]-7H-purin-6-amine Chemical compound Cc1cccc(CNc2nc(Cl)nc3nc[nH]c23)c1 RQTNGBCKFZJCGA-UHFFFAOYSA-N 0.000 description 1
- LZLLRNSIZOCRJD-UHFFFAOYSA-N 2-methyloxolane-2-carboxamide Chemical compound NC(=O)C1(C)CCCO1 LZLLRNSIZOCRJD-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 101150007969 ADORA1 gene Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 238000003650 Calcium Assay Kit Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 101000894568 Catharanthus roseus Catharanthine synthase Proteins 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 101710165567 Extracellular signal-regulated kinase 1 Proteins 0.000 description 1
- 101710165576 Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NMMIHXMBOZYNET-UHFFFAOYSA-N Methyl picolinate Chemical compound COC(=O)C1=CC=CC=N1 NMMIHXMBOZYNET-UHFFFAOYSA-N 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- DUFSCPYKJVKSLZ-UHFFFAOYSA-N N-[(3-methylphenyl)methyl]-2-(5-methylpyridin-3-yl)-7H-purin-6-amine Chemical compound CC1=CC=CC(CNC2=C3N=CNC3=NC(C3=CC(C)=CN=C3)=N2)=C1 DUFSCPYKJVKSLZ-UHFFFAOYSA-N 0.000 description 1
- CFOUQRKBDGZQKI-UHFFFAOYSA-N N-benzyl-2-ethyl-7H-purin-6-amine Chemical compound CCc1nc(NCc2ccccc2)c2[nH]cnc2n1 CFOUQRKBDGZQKI-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- PYPRPMDWAJYOCK-UHFFFAOYSA-N OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O Chemical compound OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O PYPRPMDWAJYOCK-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000170793 Phalaris canariensis Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IHNHAHWGVLXCCI-CYDGBPFRSA-N [(2s,3s,4s,5r)-3,4,5-triacetyloxyoxolan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1O[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O IHNHAHWGVLXCCI-CYDGBPFRSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000000421 anti-necrotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000000477 aza group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QRIQDCCYCOYGBJ-UHFFFAOYSA-N isocyanatosulfanyl cyanate Chemical compound N(=C=O)SOC#N QRIQDCCYCOYGBJ-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MNEFJFGMCUHZMT-NLJXWPIHSA-N methyl (2S,3S,4R,5R)-3,4-diacetyloxy-5-[6-[(3-methylphenyl)methylamino]-2-(5-methylpyridin-3-yl)purin-9-yl]oxolane-2-carboxylate Chemical compound CC(O[C@@H]([C@H]1OC(C)=O)[C@@H](C(OC)=O)O[C@H]1N1C2=NC(C3=CC(C)=CN=C3)=NC(NCC3=CC(C)=CC=C3)=C2N=C1)=O MNEFJFGMCUHZMT-NLJXWPIHSA-N 0.000 description 1
- GICJPXBBNUKKFX-QDEZUTFSSA-N methyl (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]oxolane-2-carboxylate Chemical compound COC([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC=NC(NCC3=CC(I)=CC=C3)=C2N=C1)=O GICJPXBBNUKKFX-QDEZUTFSSA-N 0.000 description 1
- WKPDVIUFXMUXNU-DTHBNOIPSA-N methyl (2s,3s,4r,5s)-3,4,5-triacetyloxyoxolane-2-carboxylate Chemical compound COC(=O)[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O WKPDVIUFXMUXNU-DTHBNOIPSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- LULXBAGMGMJJRW-UHFFFAOYSA-N n,2-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)CC(=O)N[Si](C)(C)C LULXBAGMGMJJRW-UHFFFAOYSA-N 0.000 description 1
- HGADHEBEJGWVDY-UHFFFAOYSA-N n-benzyl-2-chloro-9-(oxan-2-yl)purin-6-amine Chemical compound C=12N=CN(C3OCCCC3)C2=NC(Cl)=NC=1NCC1=CC=CC=C1 HGADHEBEJGWVDY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 150000003109 potassium Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- WCNFFKHKJLERFM-UHFFFAOYSA-N thiomorpholinyl sulfone group Chemical group N1(CCSCC1)S(=O)(=O)N1CCSCC1 WCNFFKHKJLERFM-UHFFFAOYSA-N 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- WCYWZMWISLQXQU-FIBGUPNXSA-N trideuteriomethane Chemical compound [2H][C]([2H])[2H] WCYWZMWISLQXQU-FIBGUPNXSA-N 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Definitions
- the present application relates to the field of biomedicine, in particular to a novel A3 adenosine receptor agonist and its preparation method and use.
- Adenosine or simply adenosine, is an endogenous substance that is an important regulator of local tissue function. Adenosine is ubiquitous and is released by almost all cells. In addition, through a series of extracellular enzymes, mainly including exonucleotide triphosphate diphosphate hydrolase-1 (CD39) and extracellular-5'-nucleotidase (CD73), ATP can also be decomposed in the extracellular space. directly produces adenosine. In general, adenosine concentrations increase under metabolically unfavorable conditions. For example, tissue hypoxia can lead to enhanced ATP breakdown and increased production of adenosine.
- adenosine During inflammation, the local concentration of adenosine is also increased due to the degradation of a large amount of ATP, and it exerts an anti-inflammatory effect by binding to the adenosine receptor (AR). Since adenosine is labile, adenosine generally interacts with adenosine receptors only at the locale where it is produced.
- A3 adenosine receptor also known as ADORA3
- Adenosine receptors also include 3 other subtypes, namely A1 adenosine receptor (A1R), A2A adenosine receptor (A2AR) and A2B adenosine receptor (A2BR).
- A1R A1 adenosine receptor
- A2AR A2A adenosine receptor
- A2BR A2B adenosine receptor
- Each adenosine receptor has an independent genetic code and has different physiological roles [Wang Junli et al., Medical Review, 2008, 14(12), 3585-3587].
- A3AR is mainly coupled with Gi, and it is generally believed that A3AR is mainly involved in the regulation of cells through two second messengers, namely cyclic adenosine monophosphate (cAMP) and calcium ion (Ca 2+ ).
- cAMP cyclic adenosine monophosphate
- Ca 2+ calcium ion
- A3AR can reduce the intracellular cAMP level by inhibiting the activity of adenylate cyclase, and play a corresponding regulatory role in cell growth and differentiation.
- PLC phosphatase c
- A3AR can also release calcium ions by activating phosphatase c after activation, and then calcium ions act as second messengers to initiate various cellular reactions and produce corresponding biological effects.
- A3AR can regulate a variety of important biological mechanisms and is a potential target for the treatment of various pathological diseases.
- A3AR agonists can play a huge clinical therapeutic role in the fields of anti-inflammatory, anti-cancer, anti-ischemia, analgesia, neuroprotection, myocardial protection and eye disease treatment.
- A3AR mediates beneficial anti-inflammatory effects and reduces myocardial tissue damage during reperfusion.
- Activating A3AR at the initial stage of reperfusion can significantly reduce the size of myocardial infarction and obtain myocardial protection through anti-apoptotic and necrotic effects.
- A3AR activation of A3AR during reperfusion injury can up-regulate the phosphorylation of pro-apoptotic protein (BAD), thereby reducing the The activity of caspase-3 (caspase-3) and inhibition of apoptosis, and thus exert cardioprotective effects.
- BAD pro-apoptotic protein
- caspase-3 caspase-3
- inhibition of apoptosis and thus exert cardioprotective effects.
- the cardioprotective effect of A3AR agonists has the potential to make them an adjunct therapy in patients with myocardial infarction, or to reduce reperfusion injury during cardiac surgery.
- A3AR plays a crucial role in the immunomodulatory processes possessed by adenosine.
- A3AR is widely distributed in immune cells and can effectively inhibit the chemotaxis and oxidative burst of neutrophils.
- A3AR is highly expressed on eosinophils and mediates two important anti-inflammatory functions of eosinophils, namely inhibition of degranulation and inhibition of reactive oxygen species production.
- Activation of A3AR also inhibits tumor necrosis factor (TNF-) release from human single oak cells, inhibits TNF-induced neutrophil degranulation and modulates T cell function.
- TNF- tumor necrosis factor
- A3AR also acts as an anti-inflammatory by reducing fever and energy expenditure.
- A3AR can also be used as a function of peripheral blood mononuclear cells (PBMCs), since A3AR is significantly up-regulated in patients' peripheral blood mononuclear cells (PBMCs). useful biomarkers.
- PBMCs peripheral blood mononuclear cells
- useful biomarkers Activation of A3AR reduces NF-B signaling and reduces the production of inflammatory cytokines and matrix metalloproteinases after lymphocytes obtained from patients with rheumatoid arthritis.
- A3AR agonists After colonoscopy was obtained from patients with ulcerative colitis, the use of A3AR agonists also inhibited the expression of NF-B signaling pathway and its downstream inflammatory factors in human colonic epithelial cells, thereby exerting anti-inflammatory effects [Ren Tianhua et al., International Journal of Digestive Diseases, 2018, 38(6), 407-412].
- A3AR is mainly expressed on mast cells and eosinophils and can attenuate the inflammatory response when activated with A3AR agonists. Therefore, A3AR agonists may become a new type of drug for the treatment of asthma.
- A3AR agonists can also produce immunosuppressive effects on inflammatory cells, so it is also possible to use this mechanism to develop new drugs for the treatment of rheumatoid arthritis. Consistent with this, A3AR agonists were indeed found to prevent cartilage damage, osteoclast/osteophyte formation and bone damage as well as lymphocyte pannus formation in tests with a rat arthritis model [Bar-Yehuda et al, Arthritis Rheum. 2009, 60:3061–3071].
- A3AR is overexpressed in cancer cells and underexpressed in normal cells [Gessi et al., Clin. Cancer Res. 2004, 210, 5895–5901; Madi et al., Clin. Cancer Res. ., 2004, 10, 4472–4479; Ochaion et al., Cell. Immunol. 2009, 258, 115–122].
- Adenosine can directly exert anti-tumor function through the action of A3AR on tumor cells in an agonistic manner.
- Thyroid cancer, lung cancer, breast cancer, colon cancer, liver cancer, pancreatic cancer, prostate cancer and kidney cancer are all treatable objects.
- Anticancer mechanisms of A3AR agonists may include: 1) Inhibit telomerase activity and arrest cells in G0/G1 phase. 2) Causes PI3K-dependent phosphorylation of Akt, which in turn reduces the basal phosphorylation level of extracellular signal-regulated kinase 1/2. 3) Down-regulation of Wnt and NF-B signaling pathways. 4) Activate natural killer cells and inhibit tumor development.
- Neuropathic pain is a problem that cannot be ignored and can cause great suffering to patients.
- drugs for nerve pain eg, drugs involving opioids, epinephrine, and calcium pathways
- A3AR agonists can block the signaling pathway of neuropathic pain, including pain caused by chemotherapy drugs and pain of many types of bone cancer.
- this is a promising new approach to pain relief that not only prevents or reverses pain from nerve damage, but also does not induce tolerance or addiction like opioids do [Jacobson et al. , Pain, 2020, 161:1425–1441].
- Nerve cell protection Studies have found that A3AR can protect the central nervous system after activation, and can protect the brain and retina from damage caused by ischemia, hypoxia or ischemia-reperfusion. It is a potential treatment Potential targets for various central nervous system diseases. For example, both in vivo and in vitro experiments have shown that activation of A3AR can dilate cerebral blood vessels, inhibit the adhesion and infiltration of inflammatory cells, and inhibit platelet aggregation, thereby reducing vascular endothelial damage caused by inflammatory cells.
- A3AR can also inhibit the production of oxygen free radicals and nitric oxide, reduce brain damage, improve cerebral blood flow, and prevent hypoxic depolarization of neurons, while reducing energy consumption in nerve cells and exerting neuroprotective effects .
- Activation of A3AR also prevents retinal neurodegeneration and is able to stimulate neurite outgrowth from retinal ganglion cells.
- A3AR agonists have great potential as drugs for the treatment of glaucoma, diabetic retinopathy and other retinal neurodegenerative diseases .
- A3AR has a high expression level in lung tissue.
- A3AR agonists reduce pulmonary arterial pressure while increasing pulmonary oxygenation.
- Mulloy et al a study of pulmonary ischemia-reperfusion injury by Mulloy et al [Mulloy et al., Ann. Thorac. Surg., 2013, 95(5), 1762-7]
- Chemotaxis and infiltration A3AR agonists were able to significantly reduce inflammation and improve lung function in mice.
- A3AR agonists are expected to have great clinical therapeutic effects in the treatment of respiratory diseases such as pneumonia and respiratory dysfunction.
- A3AR agonists can exert therapeutic effects in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) through three mechanisms. The three effects are anti-fat, anti-inflammatory and anti-fibrotic.
- NAFLD nonalcoholic fatty liver disease
- NASH nonalcoholic steatohepatitis
- the three effects are anti-fat, anti-inflammatory and anti-fibrotic.
- PI3K nonalcoholic fatty liver disease
- PI3K the upstream of Wnt/ ⁇ -catenin and NF- ⁇ B pathways are dominated by PI3K, and activation of A3AR can inhibit the activity of PI3K, which is shown in that activation of A3AR can reduce the protein expression level of ⁇ -SMA ( ⁇ -SMA is controlled by PI3K) control, its expression level can be used as a biomarker of liver fibrosis).
- A3AR agonists may become effective drugs for the treatment of NAFLD/NASH.
- the present application provides a series of novel compounds with both modulating or agonistic effects on A3AR activity, preparation methods of the series of compounds, pharmaceutical compositions comprising the series of compounds, and medicinal uses of the series of compounds.
- the series of compounds can be used as efficient A3AR agonists, and have various pharmacological activities such as anti-tumor, anti-inflammatory, analgesic, neuroprotective, myocardial protection, eye disease treatment and anti-infection.
- the compound synthesis method of the present application is mild, simple and easy to operate, and suitable for industrial scale-up production.
- the application provides a compound of formula I,
- R 1a and R 1b may each be independently selected from hydrogen and optionally substituted following groups: C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 2 - C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, bridged cyclyl, heterobridged cyclyl, spirocyclyl or heterospirocyclyl; Alternatively R 1a and R 1b can be taken together to form C 3 -C 10 heterocyclyl, heterobridged and heterospirocyclyl;
- R 2 may be selected from hydrogen, halogen and optionally substituted following groups: C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 2 -C 10 alkenyl , C 2 -C 10 alkynyl, 5-8 membered aryl, 5-8 membered heteroaryl, fused ring group, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, bridged ring group , heterobridged cyclyl, spirocyclyl and heterospirocyclyl;
- R 4 can be selected from hydrogen, deuterium, halogen, hydroxy and optionally substituted following groups: C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 3 - C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, heteroaryl, fused ring, C 1 -C 10 alkyl-aryl, C 1 -C 10 alkyl-heteroaryl and C 1 -C 10 alkyl-fused ring group;
- R 4a and R 4b may each be independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxy, amino, and optionally substituted C 1 -C 10 alkyl, C 1 -C 10 aminoalkyl, C 3 - C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl; or R 4a and R 4b can be taken together to form C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, heterobridged ring and heterospiro ring base;
- Y may be selected from hydrogen, deuterium, halogen, amino, hydroxy, cyano, and optionally substituted C1- C10 alkyl, C1 - C10 alkoxy, and C1 - C10 aminoalkyl .
- the compound of formula I is a compound of formula II:
- Ring A can be a 5-8 membered aryl group, a 5-8 membered heteroaryl group, or a fused ring group;
- R 1a and R 1b may each be independently selected from hydrogen and optionally substituted following groups: C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 2 - C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, bridged cyclyl, heterobridged cyclyl, spirocyclyl or heterospirocyclyl; Alternatively R 1a and R 1b can be taken together to form C 3 -C 10 heterocyclyl, heterobridged and heterospirocyclyl;
- R 4 can be selected from hydrogen, deuterium, halogen, hydroxy and optionally substituted following groups: C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 3 - C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, aryl, heteroaryl, fused ring, C 1 -C 10 alkyl-aryl, C 1 -C 10 alkyl-heteroaryl and C 1 -C 10 alkyl-fused ring group;
- R 4a and R 4b may each be independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxy, amino, and optionally substituted C 1 -C 10 alkyl, C 1 -C 10 aminoalkyl, C 3 - C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl; or R 4a and R 4b can be taken together to form C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, heterobridged ring and heterospiro ring base;
- R can be selected from amino, halogen, nitro, hydroxyl, -S(O)R, S(O) 2NHR , -C (O)R, -C(O)OR, -OC(O)R, - OC(O)OR, acetyl, cyano, amido, sulfonyl, aminocarbonyl, aminosulfonyl, phosphoryl and optionally substituted: C1 - C10 alkyl, C1 - C10 alkane Oxy group, C 1 -C 10 aminoalkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, 5-10 membered aryl, 5-10 membered heteroaryl, C 2 - C 10 alkenyl and C 2 -C 10 alkynyl, n is any integer from 0 to 9, for example n can be 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9;
- Y may be selected from hydrogen, deuterium, halogen, amino, hydroxy, cyano, and optionally substituted C1- C10 alkyl, C1 - C10 alkoxy, and C1 - C10 aminoalkyl .
- the A-ring can be selected from the following structures:
- Each of them may be substituted at optional positions with one or more R 6 .
- R 4 can be selected from:
- the R4a and R4b may each be independently selected from, but are not limited to, the following groups or structures: hydrogen, deuterium, halogen, vinyl, isopropyl, -CD3 , -CH3 , -CF3 , CH3O- , CF3O- , CH3CH2- , CH3CH2O- , CH3CH2CH2- , CF3CH2- , CF3CH2O- , or R 4a and R 4b together form the following structure:
- the compound of formula II can be a compound of formula VIII or formula IX:
- X 11 , X 12 , X 14 and X 15 can each independently be CH or N, and X 13 is independently N, O or S;
- R 1a and R 1b may each be independently selected from hydrogen and optionally substituted following groups: C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 2 - C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, bridged cyclyl, heterobridged cyclyl, spirocyclyl or heterospirocyclyl; Or R 1a and R 1b together form C 3 -C 10 heterocyclyl, heterobridged and heterospirocyclyl;
- R 4a and R 4b may each be independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxy, amino, and optionally substituted C 1 -C 10 alkyl, C 1 -C 10 aminoalkyl, C 3 - C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl; or R 4a and R 4b together form C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, heterobridged ring and heterospirocycle base;
- R can be selected from amino, halogen, nitro, hydroxyl, -S(O)R, S(O) 2NHR , -C (O)R, -C(O)OR, -OC(O)R, - OC(O)OR, acetyl, cyano, amido, sulfonyl, aminocarbonyl, aminosulfonyl, phosphoryl and optionally substituted: C1 - C10 alkyl, C1 - C10 alkane Oxy group, C 1 -C 10 aminoalkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, 5-10 membered aryl, 5-10 membered heteroaryl, C 2 - C 10 alkenyl and C 2 -C 10 alkynyl, n is any integer from 0 to 4;
- Y may be selected from hydrogen, deuterium, halogen, amino, hydroxy, cyano, and optionally substituted C1- C10 alkyl, C1 - C10 alkoxy, and C1 - C10 aminoalkyl .
- the compound of formula II is a compound of formula III:
- X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 and X 10 can be independently CH or N;
- R 1a and R 1b may each be independently selected from hydrogen and optionally substituted following groups: C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 2 - C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, bridged cyclyl, heterobridged cyclyl, spirocyclyl or heterospirocyclyl; Alternatively R 1a and R 1b can be taken together to form C 3 -C 10 heterocyclyl, heterobridged and heterospirocyclyl;
- R 4a and R 4b may each be independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxy, amino, and optionally substituted C 1 -C 10 alkyl, C 1 -C 10 aminoalkyl, C 3 - C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl; or R 4a and R 4b can be taken together to form C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, heterobridged ring and heterospiro ring base;
- R 5 and R 6 can each be independently selected from amino, halogen, nitro, hydroxyl, -S(O)R, S(O) 2NHR , -C(O)R, -C(O)OR, -OC (O)R, -OC(O)OR, acetyl, cyano, amido, sulfonyl, aminocarbonyl, aminosulfonyl, phosphoryl and optionally substituted C1 - C10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, 5-10-membered aryl, 5-10-membered hetero Aryl, C 2 -C 10 alkenyl and C 2 -C 10 alkynyl, m and n are each independently any integer from 0 to 5;
- Y may be selected from hydrogen, deuterium, halogen, amino, hydroxy, cyano, and optionally substituted C1- C10 alkyl, C1 - C10 alkoxy, and C1 - C10 aminoalkyl .
- the A ring in the compound of formula III is selected from the following structures:
- X 6 , X 7 , X 8 , X 9 and X 10 are each independently CH or N, and n is any integer from 0 to 5.
- the B ring in the compound of formula III is selected from the following structures:
- m is any integer from 0 to 5.
- the compound of formula III can be selected from the following structures:
- the R 4a and R 4b may each independently be further selected from the following groups: H, deuterium, F, -CD 3 , -CH 3 , -CF 3 , CH 3 O-, CF 3 O- , CH3CH2- , CH3CH2O- , CH3CH2CH2- , CF3CH2- and CF3CH2O- .
- the R 4a and R 4b can be H.
- the compound of formula III is a compound of formula IV:
- R 1a and R 1b may each be independently selected from hydrogen and optionally substituted following groups: C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 2 - C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, bridged cyclyl, heterobridged cyclyl, spirocyclyl or heterospirocyclyl; Alternatively R 1a and R 1b can be taken together to form C 3 -C 10 heterocyclyl, heterobridged and heterospirocyclyl;
- R 4a and R 4b may each be independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxy, amino, and optionally substituted C 1 -C 10 alkyl, C 1 -C 10 aminoalkyl, C 3 - C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl; or R 4a and R 4b can be taken together to form C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, heterobridged ring and heterospiro ring base;
- R 5 and R 6 can each be independently selected from amino, halogen, nitro, hydroxyl, -S(O)R, S(O) 2NHR , -C(O)R, -C(O)OR, -OC (O)R, -OC(O)OR, acetyl, cyano, amido, sulfonyl, aminocarbonyl, aminosulfonyl, phosphoryl and optionally substituted C1 - C10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, 5-10-membered aryl, 5-10-membered hetero Aryl, C 2 -C 10 alkenyl and C 2 -C 10 alkynyl, m and n are each independently any integer from 0 to 4;
- Y may be selected from hydrogen, deuterium, halogen, amino, hydroxy, cyano, and optionally substituted C1- C10 alkyl, C1 - C10 alkoxy, and C1 - C10 aminoalkyl .
- R 1b , R 4a , R 4b and Y can all be H, and the compound of formula IV can have the structure of formula IV-A:
- the compound of formula IV is the compound of formula VI:
- R 5 and R 6 can each be independently selected from amino, halogen, nitro, hydroxyl, -S(O)R, S(O) 2NHR , -C(O)R, -C(O)OR, -OC (O)R, -OC(O)OR, acetyl, cyano, amido, sulfonyl, aminocarbonyl, aminosulfonyl, phosphoryl and optionally substituted C1 - C10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, 5-10-membered aryl, 5-10-membered hetero Aryl, C 2 -C 10 alkenyl and C 2 -C 10 alkynyl, m and n are each independently any integer from 0 to 4;
- Y may be selected from hydrogen, deuterium, halogen, amino, hydroxy, cyano, and optionally substituted C1- C10 alkyl, C1 - C10 alkoxy, and C1 - C10 aminoalkyl .
- the compound of formula III is a compound of formula V:
- R 1a and R 1b may each be independently selected from hydrogen and optionally substituted following groups: C 1 -C 10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 2 - C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, bridged cyclyl, heterobridged cyclyl, spirocyclyl or heterospirocyclyl; Alternatively R 1a and R 1b can be taken together to form C 3 -C 10 heterocyclyl, heterobridged and heterospirocyclyl;
- R 4a and R 4b may each be independently selected from the group consisting of: hydrogen, deuterium, halogen, hydroxy, amino, and optionally substituted C 1 -C 10 alkyl, C 1 -C 10 aminoalkyl, C 3 - C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl; or R 4a and R 4b can be taken together to form C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, heterobridged ring and heterospiro ring base;
- R 5 and R 6 can each be independently selected from amino, halogen, nitro, hydroxyl, -S(O)R, S(O) 2NHR , -C(O)R, -C(O)OR, -OC (O)R, -OC(O)OR, acetyl, cyano, amido, sulfonyl, aminocarbonyl, aminosulfonyl, phosphoryl and optionally substituted C1 - C10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, 5-10-membered aryl, 5-10-membered hetero Aryl, C 2 -C 10 alkenyl and C 2 -C 10 alkynyl, n and p may each independently be 0 to 4;
- Y may be selected from hydrogen, deuterium, halogen, amino, hydroxy, cyano, and optionally substituted C1- C10 alkyl, C1 - C10 alkoxy, and C1 - C10 aminoalkyl .
- R 4a and R 4b can each independently be hydrogen, deuterium, halo, hydroxy, amino, or optionally substituted: C 1 -C 10 alkyl, C 1 -C 10 haloalkyl , C 1 -C 10 aminoalkyl.
- R 4a and R 4b can both be hydrogen.
- Y can be hydrogen or halogen.
- R 1b , R 4a , R 4b and Y can all be H, and the compound of formula V can have the structure of formula VA:
- the compound of formula V is a compound of formula VII:
- R 5 and R 6 can each be independently selected from amino, halogen, nitro, hydroxyl, -S(O)R, S(O) 2NHR , -C(O)R, -C(O)OR, -OC (O)R, -OC(O)OR, acetyl, cyano, amido, sulfonyl, aminocarbonyl, aminosulfonyl, phosphoryl and optionally substituted C1 - C10 alkyl, C 1 -C 10 alkoxy, C 1 -C 10 aminoalkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, 5-10-membered aryl, 5-10-membered hetero Aryl, C 2 -C 10 alkenyl and C 2 -C 10 alkynyl, n is any integer from 0 to 4;
- Y may be selected from hydrogen, deuterium, halogen, amino, hydroxy, cyano, and optionally substituted C1- C10 alkyl, C1 - C10 alkoxy, and C1 - C10 aminoalkyl .
- the compounds of formula I include the following compounds or pharmaceutically acceptable salts thereof:
- the compound of formula I can be selected from the following compounds:
- the present application also includes A3 receptor agonists obtained by further modification or functional group substitution, but not substantial modification, of the compounds of formula I to formula IX shown above.
- the compounds of the present application also include but are not limited to:
- the application provides solvates, hydrates, stereoisomers, tautomers, isotopic labels, metabolites, or prodrugs of compounds described herein, or pharmaceutically acceptable salts thereof.
- the present application provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound described in the present application, its pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, tautomer, isotopic label , a metabolite or prodrug, and optionally a pharmaceutically acceptable carrier.
- the present application provides the compounds described herein or pharmaceutically acceptable salts thereof, solvates, hydrates, stereoisomers, tautomers, isotopic labels, metabolites described herein Or a prodrug, or the application of the pharmaceutical composition described in this application in the preparation of an A3 adenosine receptor agonist.
- the present application provides the compounds described herein or pharmaceutically acceptable salts thereof, solvates, hydrates, stereoisomers, tautomers, isotopic labels, metabolites described herein Or prodrug, or the application of the pharmaceutical composition described in this application in the preparation of a medicament for preventing and/or treating A3 adenosine receptor-mediated or A3 adenosine receptor-related diseases.
- A3 adenosine receptor agonist refers to any molecule capable of specifically binding to the A3 adenosine receptor (A3AR) thereby fully or partially activating the receptor.
- A3AR agonists are thus molecules that exert their primary effect through the binding and activation of A3AR. It should be noted that some A3AR agonists can also interact with and activate other receptors with lower affinity.
- alkyl generally refers to a straight or branched chain saturated hydrocarbon moiety consisting solely of carbon and hydrogen atoms.
- alkyl groups include: methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and tert-butyl), pentyl base, isopentyl or hexyl, etc.
- alkyl groups may be optionally substituted on each carbon as defined in the claims. Typical substituents include, but are not limited to, fluorine, chlorine, OH, cyano and alkyl (optionally substituted), cycloalkyl, and the like.
- Cx - Cy or " Cxy ", where x is the substituent The minimum number of carbon atoms in y is the maximum number.
- C1 - C6 alkyl or " C1-6 alkyl” refers to an alkyl substituent containing 1 to 6 carbon atoms.
- C3-C6cycloalkyl or C3-6cycloalkyl refers to a saturated cycloalkyl group containing 3 to 6 carbon ring atoms.
- aminoalkyl generally refers to an alkyl group substituted with a primary, secondary or tertiary amino group.
- the aminoalkyl group can include one or more primary, secondary and/or tertiary amine groups and 1 to about 12 carbon atoms, 1 to about 10 carbon atoms, 1 to about 8 carbon atoms , those aminoalkyl groups of 1, 2, 3, 4, 5 or 6 carbon atoms.
- Non-limiting examples of such aminoalkyl groups include aminomethyl, aminoethyl, and the like.
- cycloalkyl generally refers to fully hydrogenated, mono-, bi-, or tricyclic non-aromatic rings containing 3 to 10 carbons. Accordingly, a cycloalkyl group may be a monocyclic ring, typically containing from 3 to 7 ring atoms. Examples include, but are not limited to: cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Alternatively, 2 or 3 rings can be fused together, eg, bicyclodecyl and decalinyl.
- cycloalkyl also includes bridged bicycloalkyl systems such as, but not limited to, bicyclo[2.2.1]heptane and bicyclo[1.1.1]pentane.
- cycloalkyl groups may be optionally substituted with 1 to 5 of the above-mentioned suitable substituents, as appropriate, eg, fluorine, chlorine, deuterium, cyano, trifluoromethyl, C1 - C6alkoxy group, trifluoromethoxy, difluoromethoxy or C 1 -C 6 alkyl.
- heterocycloalkyl generally refers to a monovalent saturated moiety consisting of one to three rings having one, two, three or four heteroatoms (selected from N, O or S) and 3 to 10 carbons atom. Heterocycloalkyl groups may be optionally substituted as defined herein.
- heterocycloalkyl moieties include, but are not limited to: optionally substituted piperidinyl, piperazinyl, homopiperazinyl, aza base, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, imidazolidinyl, pyridyl, pyridazinyl, pyrimidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazole Alkyl, quinuclidinyl, quinolyl, isoquinolyl, benzimidazolyl, thiadiazolidinyl, benzothiazolidinyl, benzoazolylidinyl, dihydrofuranyl, tetrahydrofuran base, dihydropyranyl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorph
- heterocycloalkyl groups may be optionally substituted with 1 to 5 suitable substituents as defined herein, for example, fluorine, chlorine, deuterium, cyano, trifluoromethyl, C1 - C6alkoxy, C 6 -C 10 aryloxy, trifluoromethoxy, difluoromethoxy or C 1 -C 6 alkyl.
- alkoxy and alkyloxy generally refer to moieties of formula -OR, wherein R is a linear saturated alkyl or branched saturated alkyl moiety as defined herein bonded through an oxygen atom. Alkoxy groups may be optionally substituted as defined herein. Non-limiting examples of such alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentoxy, and the like.
- haloalkyl generally refers to an alkyl group substituted with one or more halogen substituents.
- halogen or halo generally refers to -F, -Cl, -Br or -I.
- alkenyl generally refers to partially unsaturated branched or straight chain hydrocarbons having at least one carbon-carbon double bond. Alkenyl groups can be optionally substituted.
- the terms “C 2 -C 3 alkenyl”, “C 2 -C 4 alkenyl”, “C 2 -C 5 alkenyl”, “C 2 -C 6 alkenyl”, “C 2 -C 5 alkenyl”"C7alkenyl” and “C2 - C8alkenyl generally refer to alkenyl groups containing at least 2 , and up to 3, 4, 5, 6, 7, or 8 carbon atoms, respectively.
- an alkenyl group generally refers to a C2 - C6 alkenyl group.
- alkenyl groups include vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, and the like.
- alkynyl generally refers to partially unsaturated branched or straight chain hydrocarbons having at least one carbon-carbon triple bond. Alkynyl groups can be optionally substituted.
- the terms “C 2 -C 3 alkynyl”, “C 2 -C 4 alkynyl”, “C 2 -C 5 alkynyl”, “C 2 -C 6 alkynyl”, “C 2 -C alkynyl”” C7alkynyl " and “C2 - C8alkynyl” generally refer to alkynyl groups containing at least 2, and up to 3, 4, 5, 6, 7, or 8 carbon atoms, respectively.
- an alkynyl group is typically a C2 - C6alkynyl group.
- alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, and decynyl, and the like .
- cycloalkyl generally refers to 3-10 membered, or 3-9 membered, or 3-8 membered, or 3-7 membered, or 3-6 membered, or 3-5 membered, or 3-4 membered Hydrocarbon and can be monocyclic or bicyclic.
- the ring may be saturated or may have some degree of unsaturation.
- Cycloalkyl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3 or 4 atoms of each ring of a cycloalkyl group may be substituted with substituents.
- Non-limiting examples of cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, cyclobutyl, cycloheptyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, and cyclohexadiene Base et al.
- aryl generally refers to a hydrocarbon monocyclic or bicyclic aromatic ring system, wherein such rings may be fused. If the rings are fused, one of the rings must be fully unsaturated, and the fused ring can be fully saturated, partially unsaturated, or fully unsaturated.
- fused means that the second ring exists (ie, connects or forms) with the first ring sharing (ie, sharing) two adjacent atoms.
- aryl includes aromatic groups such as phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, 4-(pyridin-3-yl)phenyl, 2,3-dihydro-1H Indenyl and 1,2,3,4-tetrahydronaphthyl.
- the aryl group may be optionally substituted with 1 to 5 of the above-mentioned suitable substituents, as the case may be.
- heteroaryl generally refers to an aromatic 5-10 membered ring system wherein the heteroatoms are selected from O, N or S and the remaining ring atoms are carbon (with appropriate hydrogen atoms unless otherwise specified) .
- Heteroaryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heteroaryl group may be substituted with substituents.
- heteroaryl groups include pyridyl, furyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl , isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoquinolinyl and indazolyl and the like.
- the number of atoms in a ring substituent containing one or more heteroatoms is represented by the prefix "x- to y-membered", where x is the minimum number of atoms forming the ring portion of the substituent and y is the maximum number.
- x is the minimum number of atoms forming the ring portion of the substituent and y is the maximum number.
- “5 to 6 membered heteroaryl” refers to a heteroaryl group containing 5 to 6 atoms in the ring portion of the heteroaryl group, including one or more heteroatoms, which may be selected from nitrogen, oxygen and sulfur.
- fused ring group generally refers to a saturated or unsaturated fused ring system, and refers to a non-aromatic bicyclic ring system, at least one of which is non-aromatic. Such systems may contain independent or conjugated states of unsaturation.
- Each ring in the fused bicyclic ring is either carbocyclic or heteroalicyclic, examples of which include, but are not limited to, hexahydro-furo[3,2-b]furanyl, 2,3,3a,4 ,7,7a-hexahydro-1H-indenyl, 7-azabicyclo[2.2.1]heptyl, fused bicyclo[3.3.0]octyl, fused bicyclo[3.1.0]hexyl , 1,2,3,4,4a,5,8,8a-octahydronaphthyl, 1,2,3,4-tetrahydronaphthalene, 2,3-dihydroindene, which are included in the fused bicyclic within the system.
- spirocyclyl generally refers to a polycyclic group in which two carbocyclic rings share one carbon atom.
- Heterospirocyclyl generally refers to a polycyclic group in which two monocyclic rings share one carbon atom, wherein the two rings may contain one or more heteroatoms.
- bridged cyclic group generally refers to a cyclic group in which any two carbon rings in the group share two carbon atoms that are not directly connected, and can be classified into bicyclic, tricyclic, tetracyclic, etc.
- Heterobridged cyclyl generally refers to a polycyclic heterocyclyl in which two rings share two non-adjacent carbon atoms or heteroatoms.
- optionally substituted generally means that the group in question may or may not be substituted with one or more additional groups, without limitation, which may be individually and independently selected from alkyl, alkenyl, , alkynyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, hydroxyl, alkoxy, mercapto, cyano, acetyl, deuterium, halogen, carbonyl, thiocarbonyl, isocyanato, sulfur Cyanate, isothiocyanate, nitro, amido, sulfonyl, phosphoryl, haloalkyl, fluoroalkyl and amino groups including mono- and di-substituted amino groups, and protected derivatives thereof.
- additional groups may be individually and independently selected from alkyl, alkenyl, , alkynyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, hydroxyl, alkoxy, mercapto, cyan
- salts generally refers to pharmaceutically acceptable organic or inorganic salts of the compounds of the present application.
- Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate , lactate, salicylate, acid citrate, tartrate, oleate, tannin, pantothenate, hydrogen tartrate, ascorbate, succinate, maleate, gentian acid salt, fumarate, gluconate, glucuronate, sugar salt, formate, benzoate, glutamate, mesylate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate (i.e.
- a pharmaceutically acceptable salt may involve the inclusion of another molecule, such as an acetate ion, a succinate ion, or other counterion.
- the counterion can be any organic or inorganic moiety that stabilizes the charge on the parent compound.
- pharmaceutically acceptable salts may have more than one charged atom in their structure. In instances where multiple charged atoms are part of a pharmaceutically acceptable salt, the salt may have multiple counter ions. Thus, a pharmaceutically acceptable salt may have one or more charged atoms and/or one or more counter ions.
- solvate generally refers to an association (assocI-Btion) or complex (complex) of one or more solvent molecules with a compound of the present application.
- solvate-forming solvents include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.
- hydrate refers to a complex in which the solvent molecule is water.
- isomer or “stereoisomer” generally refers to compounds that have the same chemical composition but differ in the arrangement of atoms or groups in space.
- tautomer generally refers to structural isomers having different energies that can be interconverted through a low energy barrier.
- proton tautomers also known as proton tautomers
- Valence tautomers involve interconversion by recombining some of the bonding electrons.
- the subject matter disclosed herein also includes isotopically labeled forms of the compounds described herein, isotopes including atoms having the same atomic number but different mass numbers.
- isotopes that can be incorporated into the compounds described herein, and pharmaceutically acceptable salts thereof, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, eg, 2 H, 3 H , 11 C, 13 C, 14 C, 15 N, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I and 125 I.
- metabolite generally refers to a product produced by metabolizing a particular compound or salt thereof in the body. Metabolites of compounds can be identified using routine techniques known in the art and their activity determined using assays as described herein. Such products may result from, for example, oxidation, hydroxylation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound. Accordingly, the present application includes metabolites of compounds of the present application, including compounds produced by a method comprising contacting a compound of the present application with a mammal for a period of time sufficient to produce the metabolites thereof.
- prodrug or “prodrug” generally refers to a compound that is a prodrug that, when administered to a subject, undergoes chemical transformation through metabolic or chemical processes to yield a compound of the present application or a salt thereof.
- references to prodrugs are well known in the art (see, eg, Berge et al. (1977) "Pharmaceutl-Dal Salts", J. Pharm. Sci. 66: 1-19).
- prodrug moieties include substituted and unsubstituted, branched or unbranched lower alkyl ester moieties (eg, propionate), lower alkenyl esters, di-lower alkyl-amino lower alkyl esters), (eg, dimethylaminoethyl ester), amido lower alkyl esters (eg, acetoxymethyl ester), acyloxy lower alkyl esters (eg, pivaloyloxy methyl esters), aryl esters (phenyl esters), aryl-lower alkyl esters (eg, benzyl esters), substituted (eg, substituted with methyl, halogen, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower alkyl amides, di-lower alkyl amides and hydroxyamides. Also included are prodrugs that are converted to the active form by other mechanisms in vivo
- lower when used in connection with an organic group or compound generally means that the compound or group may be branched or unbranched, having up to and including 7 carbon atoms, eg, 1-6 carbon atoms, 1-5 carbon atoms or 1-4 carbon atoms.
- esters may form esters, which are also within the scope of the present application.
- ester generally refers to esters that hydrolyze in vivo and include those esters that are readily broken down in humans to leave the parent compound or salt thereof.
- Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids.
- Representative examples of specific esters include, but are not limited to, formate, acetate, propionate, butyrate, acrylate, and ethyl succinate.
- the compounds of the present invention have asymmetric carbon atoms.
- This application may use solid lines solid wedge or dashed wedge to describe the carbon-carbon bonds of the compounds of the present invention.
- the use of a solid line to describe a bond to an asymmetric carbon atom is generally meant to include all possible stereoisomers at that carbon atom (eg, specific enantiomers, racemic mixtures, etc.). Bonds to asymmetric carbon atoms are described using solid or dashed wedges, and are often used to denote stereoisomers.
- Compounds of formula I may contain more than one asymmetric carbon atom.
- the use of a solid line describing a bond to an asymmetric carbon atom is meant to include all possible stereoisomers.
- the compounds of formula I may exist in the form of enantiomers and diastereomers or racemates and mixtures thereof.
- carrier may include pharmaceutically acceptable carriers, excipients or stabilizers which are nontoxic to cells or mammals at the dosages and concentrations employed.
- the physiologically acceptable carrier is usually a pH buffered aqueous solution.
- physiologically acceptable carriers include buffers, such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin.
- the pharmaceutically acceptable carrier is a non-naturally occurring pharmaceutically acceptable carrier.
- preventing and/or treating includes not only preventing and/or treating a disease, but generally preventing the onset of a disease, slowing or reversing the progression of a disease, preventing or slowing the onset of one or more symptoms associated with a disease, reducing and /or reduce one or more symptoms associated with the disease, reduce the severity and/or duration of the disease and/or any symptoms associated therewith and/or prevent further severity of the disease and/or any symptoms associated therewith Increase, prevent, reduce or reverse any physiological damage caused by the disease, as well as any pharmacological effects that are generally beneficial to the patient being treated.
- the compositions of the present application do not need to achieve complete cure or eradication of any symptom or manifestation of the disease to form a viable therapeutic.
- a drug used as a therapeutic agent can reduce the severity of a given disease state, but need not eliminate every manifestation of the disease to be considered a useful therapeutic agent.
- prophylactically administered treatments do not need to be completely effective in preventing the onset of the disorder to constitute a viable prophylactic. Simply reducing the effect of the disease in the subject (for example, by reducing the number or severity of its symptoms, or by increasing the effectiveness of another treatment, or by producing another beneficial effect), or by reducing the occurrence of the disease or The possibility of deterioration is enough.
- administration includes the route by which the compound is introduced into a subject to achieve its intended function.
- routes of administration include injection (subcutaneous, intravenous, parenteral, intraperitoneal, intrathecal), topical, oral, inhalation, rectal, and transdermal.
- an effective amount includes that amount, in the dosage and for the period of time necessary, to achieve the desired result.
- An effective amount of a compound may vary depending on factors such as the subject's disease state, age, and weight, and the ability of the compound to elicit a desired response in the subject. Dosage regimens can be adjusted to provide optimal therapeutic response.
- a "therapeutically effective amount” refers to an amount of a compound of the present application that (i) treats or prevents a particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more symptoms of a particular disease, condition or disorder, or (iii) preventing or delaying the onset of one or more symptoms of a particular disease, condition or disorder described herein.
- the therapeutically effective amount of the drug reduces the number of cancer cells; reduces tumor size; inhibits (ie, to some extent slows and preferably stops) infiltration of cancer cells into peripheral organs; inhibits ( That is, to some extent slow and preferably stop) tumor metastasis; to some extent inhibit tumor growth; and/or to some extent alleviate one or more symptoms associated with the cancer.
- the drug can prevent and/or kill the growth of existing cancer cells, it can be cytostatic and/or cytotoxic.
- efficacy can be measured, for example, by assessing the time to disease progression (TTP) and/or determining the response rate (RR).
- the term "contacting" generally refers to two or more substances of different types being brought into contact together in any order, in any manner, and for any length of time.
- the interaction between A3R agonists and A3R comprises one or more hydrogen bonds, covalent bonds, ionic bonds, hydrophobic contacts, and/or van der Waals contacts.
- subject or “patient” generally refers to animals, such as mammals, including but not limited to primates (eg, humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, and small mouse etc.
- the subject is a human.
- the present application provides a method for preparing the compound of formula I, which comprises the following steps:
- X is chlorine, bromine or iodine
- PEG is the protecting group of hydroxyl group, and the two PEG protecting groups on compound I-1-6 can be connected to one protecting group to protect two hydroxyl groups at the same time
- R 1a , R 1b , R 2 , R 4 , R 4a and R 4b are as defined for the compounds of formula I described.
- the present application provides a method for preparing the compound of formula I, which comprises the following steps:
- X is chlorine, bromine or iodine
- PEG is the protecting group of hydroxyl group, and the two PEG protecting groups on compound I-2-2 can be connected to one protecting group to protect two hydroxyl groups at the same time
- R 1a , R 1b , R 2 , R 4 , R 4a and R 4b are as defined for the compounds of formula I described.
- the present application provides a method for preparing the compound of formula I, which comprises the following steps:
- X is chlorine, bromine or iodine
- PEG is the protecting group of hydroxyl group, and the two PEG protecting groups on compound I-3-7 can be connected to one protecting group to protect two hydroxyl groups at the same time
- R 1a , R 1b , R 2 , R 4 , R 4a and R 4b are as defined for the compounds of formula I described.
- the present application provides a method for preparing the compound of formula I, which comprises the following steps:
- X is chlorine, bromine or iodine
- PEG is the protecting group of hydroxyl, and the two PEG protecting groups on compound I-4-7 can be connected to one protecting group to protect two hydroxyls at the same time
- R 1a , R 1b , R 2 , R 4 , R 4a and R 4b are as defined for the compounds of formula I described.
- the present application provides a method for preparing the compound of formula I, which comprises the following steps:
- X is chlorine, bromine or iodine
- PEG is the protecting group of hydroxyl group, and the two PEG protecting groups on compound I-5-2 can be connected to one protecting group to protect two hydroxyl groups at the same time
- R 1a , R 1b , R 2 , R 4 , R 4a and R 4b are as defined for the compounds of formula I described.
- the present application provides a method for preparing the compound of formula I, which comprises the following steps:
- X is chlorine, bromine or iodine
- PEG is the protecting group of hydroxyl group, and the two PEG protecting groups on compound I-6-1 can be connected to one protecting group to protect two hydroxyl groups at the same time
- R 1a , R 1b , R 2 , R 4 , R 4a and R 4b are as defined for the compounds of formula I described.
- the present application provides a method for preparing the compound of formula I, which comprises the following steps:
- X is chlorine, bromine or iodine
- PEG is the protecting group of hydroxyl group, and the two PEG protecting groups on compound I-6-1 can be connected to one protecting group to protect two hydroxyl groups at the same time
- R 1a , R 1b , R 2 , R 4 , R 4a and R 4b are as defined for the compounds of formula I described.
- the present application provides a method of preventing and/or treating A3 adenosine receptor-mediated or A3 adenosine receptor-related diseases, which may comprise: administering to a subject in need thereof a therapeutically effective amount of the disease described herein.
- the diseases that can be treated with an A3 adenosine receptor agonist can include:
- Cancer such as non-small cell lung cancer, small cell lung cancer, stomach cancer, liver cancer, thyroid cancer, cervical cancer, ovarian cancer, breast cancer, colon cancer, liver cancer, pancreatic cancer, prostate cancer and kidney cancer;
- neuropathic pain such as that from chemotherapy
- neurodegenerative diseases such as rheumatoid arthritis and knee osteoarthritis
- Ischemia-reperfusion injury ischemia, such as ischemic tissue caused by ischemia, ischemic or hypoxic tissue subject to ischemic necrosis or infarction resulting in irreversible organ damage, these tissues include but are not limited to muscle, brain, Kidneys and lungs.
- Ischemic diseases include cerebral thrombosis, renal ischemia, pulmonary ischemia, ischemic cardiomyopathy and myocardial ischemia-reperfusion and other related diseases;
- Viral infections inhibits the replication of related viruses in cells, such as COVID-19
- NASH nonalcoholic steatohepatitis
- Eye diseases such as keratoconjunctivitis sicca, uveitis, increased intraocular pressure or glaucoma.
- administration of at least one additional therapeutic means, such as other cancer or immune disease therapeutics, to a subject in need thereof may also be included.
- the present application provides a medicament for preventing and/or treating A3 adenosine receptor-mediated or A3 adenosine receptor-related diseases, the medicament comprising the compound described in the present application or its pharmaceutically acceptable Acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopic labels, metabolites or prodrugs described herein, or pharmaceutical compositions described herein.
- the present application provides a method for modulating the activity of A3 adenosine receptors, which may include: combining A3 adenosine receptors with the compounds described in the present application or pharmaceutically acceptable salts thereof, the solvent described in the present application Compounds, hydrates, stereoisomers, tautomers, isotopic labels, metabolites or prodrugs, or pharmaceutical compositions described herein.
- modulating A3 adenosine receptor activity can include agonizing A3 adenosine receptor activity.
- Embodiment 2 react according to S1-S5 in embodiment 1, obtain the compound in the following table:
- Example 3 the obtained target compound was a white solid (47 mg, 47% yield).
- the reaction was quenched by adding water, extracted with ethyl acetate, the organic layers were combined, the organic layers were washed with water and saturated brine respectively, the organic layers were collected, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure Get crude product.
- 2,6-Dichloro-9H-purine (10g, 53mmol) was dissolved in anhydrous acetonitrile (60mL) solvent, followed by adding trimethylsilyl trifluoromethanesulfonate (12.9g, 58.2mmol) and N,O- Bistrimethylsilylacetamide (11.8 g, 58.2 mmol), after stirring at room temperature for 2 hours, compound 1,2,3,5-tetra-O-acetyl ⁇ -L-ribofuranose was added to the reaction solution, and the temperature was raised to 80°C The reaction was completed for 3 hours, and the reaction was detected by TLC.
- the reaction was quenched by adding water, extracted with ethyl acetate, the organic layers were combined, the organic layers were washed with water and saturated brine respectively, the organic layers were collected, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude product.
- the reaction was quenched by adding water, adjusted to pH>7 with sodium hydroxide solution, extracted with ethyl acetate, collected the aqueous layer, adjusted to pH ⁇ 7 with concentrated hydrochloric acid, extracted with ethyl acetate, organic The layer was washed with water and saturated brine, and the organic layer was collected, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product as a yellow solid (3.5 g, 63% yield).
- Example 6 the title compound was obtained as a white solid (55 mg, 10% yield).
- step S2 in Example 6 the target compound was obtained as a white solid (21 g, 83% yield).
- step S6 in Example 6 the title compound was obtained as a white solid (4.4 g, 61% yield).
- Embodiment 9 with reference to the specific operation of embodiment 8, obtain the compound in the following table:
- Embodiment 11 with reference to the specific operation of embodiment 10, obtain the compound in the following table:
- Example 13 With reference to Example 12, the compounds shown in the following table were obtained:
- Embodiment 15 With reference to the specific steps of Embodiment 14, the compounds listed in the following table are obtained:
- N-3-methylbenzyl-2-(5-methylpyridin-3-yl)-9-(tetrahydro-2H-pyran)-2-yl)-9H-purin-6-amine (4.1 g, 9.9 mmol) was dissolved in a mixed solvent of TFA (5 mL) and water (3 mL), reacted at room temperature for 3 hours, and the reaction was completed by TLC detection. First, the pH was adjusted to >7 with aqueous sodium bicarbonate solution, filtered, and the filter cake was slurried and dried with ethyl acetate to obtain the target compound as a white solid (2.5 g, 90% yield).
- Embodiment 17 with reference to the specific steps of embodiment 16, obtain the compound in the following table
- Example 19 Refer to the specific operation of Example 18 to obtain the compounds in the following table
- Example 22 Refer to the corresponding steps of Example 21 to obtain the compounds in the following table
- 6-(2,6-Dichloropurin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxazole-4-carboxylic acid carboxamide-d3 200 mg, 0.51 mmol
- isopropylamine 60 mg, 1.02 mmol
- DIPEA 132 mg, 49.7 mmol
- Embodiment 24 With reference to the specific operation of embodiment 23, obtain the compound in the following table
- Example 26 Effect of compounds on intracellular cAMP levels via A3 adenosine receptor agonism
- CHO cells stably expressing the ADORA3 receptor were harvested and cells were counted using a Countess cytometer prior to assay. Only cells with >85% viability were used for the following assays.
- Ratio cpd The ratio of the emissivity of the test compound
- Ratio Low Control The ratio of low emissivity
- Ratio High Control The ratio of high emissivity
- NECA (CAS: 35920-39-9) is a non-selective A3 adenosine receptor agonist, used as a positive control drug. It can be seen from the above data that the compounds in the list all exhibit high A3 adenosine receptor agonistic activity through the test of cAMP levels in cells.
- Example 27 FLIPR assay (calcium flux assay) for the ability of compounds to activate the A3 adenosine receptor
- ADORA3 receptors use the cultured cells for cell seeding: aspirate the medium and wash the cells twice with 10 mL of DPBS. Add 2 mL of 0.05% EDTA-trypsin and incubate at 37 °C for 1 min. Then 10 mL of medium was added to stop digestion, and the cell suspension was transferred to a 50 mL conical tube.
- Fluo-4 DirectTM crystals Thaw a vial of Fluo-4 DirectTM crystals and add 10 mL of FLIPR Assay Buffer to the vial. Then 0.2 mL of 250 mM probe solution was added to each 10 mL of Fluo-4 DirectTM crystals to give a final assay concentration of 2.5 mM. Vortex and let stand for >5 minutes, protected from light. 2x Fluo-4 DirectTM dye was prepared fresh daily.
- ADORA3 receptors First, remove the cell plate from the incubator. The medium was then aspirated and 20 ⁇ l of FLIPR assay buffer was added. Incubator for 45 minutes at room temperature for 15 minutes.
- Efficacy (%) maximum activation of test compound/maximum activation of NECA*100.
- NECA (CAS: 35920-39-9) is a non-selective A3 adenosine receptor agonist, used as a positive control drug. It can be seen from the above data that the compounds in the list all exhibit high A3 adenosine receptor agonistic activity through the test of in vivo calcium flux level (FLIPR assay).
- Example 28 Compound SD rat in vivo pharmacokinetic test
- the animal species in this experiment is SD rats, 3 rats in each group, and the drugs are administered in a mixed manner, that is, multiple (1-6) different compounds are simultaneously administered to SD rats in the same group.
- the vehicle used in the drug is 5% DMSO+5% Solutol+90% (0.5% methylcellulose M450), and the administration method is intragastric administration (IG).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
化合物编号 | EC50(nM) | 化合物编号 | EC50(nM) |
24 | 5.77 | 226 | 1.20 |
70 | 1.23 | 230 | 8.68 |
71 | <0.51 | 245 | 0.28 |
92 | <0.51 | 246 | 1.18 |
102 | 1.41 | 247 | 4.16 |
106 | 3.02 | 254 | 9.51 |
107 | 5.22 | 255 | 8.58 |
108 | 1.58 | 256 | 11.62 |
111 | 7.32 | 282 | 4.00 |
112 | 3.53 | 284 | 2.85 |
159 | 4.42 | 289 | 6.81 |
160 | 3.53 | 290 | 12.43 |
161 | 0.74 | 293 | <0.51 |
177 | 2.08 | 294 | 2.62 |
179 | 9.44 | 296 | 1.28 |
182 | <0.51 | 300 | 2.13 |
183 | <0.51 | 301 | 3.78 |
184 | <0.51 | 302 | 2.26 |
185 | <0.51 | 305 | 2.73 |
186 | <0.51 | 306 | 5.81 |
187 | 14.50 | 307 | 9.40 |
222 | 0.89 | 308 | 3.27 |
223 | 15.24 | 312 | <0.51 |
224 | 1.34 | 325 | 9.62 |
NECA | 3.10 | / | / |
化合物编号 | EC50(nM) | 化合物编号 | EC50(nM) |
42 | 12.73 | 193 | 10.87 |
43 | 11.41 | 194 | 10.65 |
71 | 1.929 | 226 | 33.55 |
72 | 20.58 | 227 | 3.528 |
73 | 29.57 | 231 | 11.19 |
90 | 25.25 | 256 | 98.48 |
106 | 17.59 | 293 | 3.27 |
112 | 44.36 | 296 | 53.57 |
159 | 59.27 | 297 | 12.92 |
177 | 70.30 | 298 | 37.03 |
183 | 9.07 | 299 | 19.43 |
184 | 13.00 | 305 | 10.92 |
186 | 11.80 | 306 | 39.18 |
190 | 9.06 | 308 | 71.40 |
191 | 5.29 | 312 | 4.05 |
192 | 9.24 | NECA | 9.7-35.49 |
Claims (15)
- 式I的化合物,或其药学上可接受的盐,其中:R 1a和R 1b各自独立地选自氢和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 1-C 10氨基烷基、C 3-C 10环烷基、C 3-C 10杂环烷基、桥环基、杂桥环基、螺环基或杂螺环基;或者R 1a和R 1b一起形成C 3-C 10杂环基、杂桥环基和杂螺环基;R 2选自氢、卤素和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 1-C 10氨基烷基、C 2-C 10烯基、C 2-C 10炔基、5-8元芳基、5-8元杂芳基、稠环基、C 3-C 10环烷基、C 3-C 10杂环烷基、桥环基、杂桥环基、螺环基和杂螺环基;R 4选自氢、氘、卤素、羟基和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 1-C 10氨基烷基、C 3-C 10环烷基、C 3-C 10杂环烷基、芳基、杂芳基、稠环基、C 1-C 10烷基-芳基、C 1-C 10烷基-杂芳基和C 1-C 10烷基-稠环基;R 4a和R 4b各自独立地选自:氢、氘、卤素、羟基、氨基和任选取代的以下基团:C 1-C 10烷基、C 1-C 10氨基烷基、C 3-C 10环烷基、C 3-C 10杂环烷基;或者R 4a和R 4b一起形成C 3-C 10环烷基、C 3-C 10杂环基、杂桥环基和杂螺环基;Y为氢。
- 根据权利要求1所述的式I的化合物,其为式II的化合物:或其药学上可接受的盐,其中:环A为5-8元芳基、5-8元杂芳基、稠环基;R 1a选自氢和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 1-C 10氨基烷基、C 3-C 10环烷基、C 3-C 10杂环烷基、桥环基、杂桥环基、螺环基或杂螺环基;或者R 1a和R 1b一起形成C 3-C 10杂环基、杂桥环基和杂螺环基;R 4选自氢、氘、卤素、羟基和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 1-C 10氨基烷基、C 3-C 10环烷基、C 3-C 10杂环烷基、芳基、杂芳基、稠环基、C 1-C 10烷基-芳基、C 1-C 10烷基-杂芳基和C 1-C 10烷基-稠环基;R 4a和R 4b各自独立地选自:氢、氘、卤素、羟基、氨基和任选取代的以下基团:C 1-C 10烷基、C 1-C 10氨基烷基、C 3-C 10环烷基、C 3-C 10杂环烷基;或者R 4a和R 4b一起形成C 3-C 10环烷基、C 3-C 10杂环基、杂桥环基和杂螺环基;R 6选自氨基、卤素、硝基、羟基、乙酰基、氰基、酰胺基、磺酰基、磷酰基和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 2-C 10烯基和C 2-C 10炔基,n为0至9中的任意整数;R 1b和Y为氢。
- 根据权利要求2所述的式II的化合物,其为式III的化合物:或其药学上可接受的盐,其中:X 1,X 2,X 3,X 4,X 5,X 6,X 7,X 8,X 9和X 10各自独立的为CH或N;R 1a选自氢和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 1-C 10氨基烷基、C 3-C 10环烷基、C 3-C 10杂环烷基、桥环基、杂桥环基、螺环基或杂螺环基;或者R 1a和R 1b一起形成C 3-C 10杂环基、杂桥环基和杂螺环基;R 4a和R 4b各自独立地选自:氢、氘、卤素、羟基、氨基和任选取代的以下基团:C 1-C 10烷基、C 1-C 10氨基烷基、C 3-C 10环烷基、C 3-C 10杂环烷基;或者R 4a和R 4b一起形成C 3-C 10环烷基、C 3-C 10杂环基、杂桥环基和杂螺环基;R 5和R 6各自独立地选自氨基、卤素、硝基、羟基、乙酰基、氰基、酰胺基、磺酰基、磷酰基和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 2-C 10烯基和C 2-C 10炔基,m和n各自独立的为0至5的任意整数;R 1b和Y为氢。
- 根据权利要求3所述的式III的化合物,其为式IV的化合物:或其药学上可接受的盐,其中:R 1a选自氢和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 1-C 10氨基烷基、C 3-C 10环烷基、C 3-C 10杂环烷基、桥环基、杂桥环基、螺环基或杂螺环基;或者R 1a和R 1b一起形成C 3-C 10杂环基、杂桥环基和杂螺环基;R 5和R 6各自独立地选自氨基、卤素、硝基、羟基、乙酰基、氰基、酰胺基、磺酰基、磷酰基和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 2-C 10烯基和C 2-C 10炔基,m和n各自独立的为0至4中的任意整数;R 1b、R 4a、R 4b和Y均为氢。
- 根据权利要求3所述的式III的化合物,其为式V的化合物,或其药学上可接受的盐,其中:R 1a选自氢和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 1-C 10氨基烷基、C 3-C 10环烷基、C 3-C 10杂环烷基、桥环基、杂桥环基、螺环基或杂螺环基;或者R 1a和R 1b一起形成C 3-C 10杂环基、杂桥环基和杂螺环基;R 5和R 6各自独立地选自氨基、卤素、硝基、羟基、乙酰基、氰基、酰胺基、磺酰基、磷酰基和任选取代的以下基团:C 1-C 10烷基、C 1-C 10烷氧基、C 2-C 10烯基和C 2-C 10炔基;m为0至5中的任意整数,n为0至4中的任意整数;R 1b、R 4a、R 4b和Y均为氢。
- 根据权利要求1-9中任一项所述的式I的化合物,所述任选取代的基团包括取代或未取代的基团,其中任选取代的基团的取代基包括:氘、卤素、-CN、=O、=N-OH、=N-OR、=N-R、OR、-C(O)R、-C(O)OR、-OC(O)R、-OC(O)OR、-C(O)NHR、-C(O)NR 2、-OC(O)NHR、-OC(O)NR 2、-SR-、-S(O)R、-S(O) 2R、-NHR、-N(R) 2、-NHC(O)R、-NRC(O)R、-NHC(O)OR、-NRC(O)OR、S(O) 2NHR、-S(O) 2N(R) 2、-NHS(O) 2NR 2、-NRS(O) 2NR 2、-NHS(O) 2R、-NRS(O) 2R、C 1-C 8烷基、C 1-C 8烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 8烷基、和卤素取代的C 1-C 8烷氧基,其中各R独立选自氢、氘、卤素、C 1-C 8烷基、C 1-C 8烷氧基、芳基、杂芳基、环烷基、杂环烷基、卤素取代的C 1-C 8烷基、和卤素取代的C 1-C 8烷氧基。
- 根据权利要求1-10中任一项所述的式I的化合物,其包括以下化合物或其药学上可接受的盐:(2S,3S,4R,5R)-5-(6-(3-碘代苄基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-碘代苯氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(2,2,2-三氟乙基)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-碘代苄基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲氧基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-碘代苄基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N'-甲基-四氢呋喃-2-碳酰肼;(2S,3S,4R,5R)-5-(6-(3-碘代苄基氨基)-9H-嘌呤-9-基)-3,4-二羟基四氢呋喃-2-碳酰肼;(2S,3S,4R,5R)-5-(6-(3-碘代苄基氨基)-9H-嘌呤-9-基)-N,3,4-三羟基四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-2-(6-(苄基氨基)-9H-嘌呤-9-基)-3,4-二羟基四氢呋喃-5-羰基氨基甲酸乙酯;(2S,3S,4R,5R)-5-(6-(3-碘代苄基氨基)-2-氯-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(2-氯-6-((甲基-d3)-氨基)-9H-嘌呤-9-基)-3,4-二羟基-N- 甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(呋喃-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(呋喃-2-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(1-甲基-1H-吡唑-4-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(1-甲基-1H-吡唑-4-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5,6-二甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(6-氰基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-氰基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(4-氰基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-(吗啉甲基)吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-苯基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(噻吩-2-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(噻吩-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-(三氟甲基)吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-环丙基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-3-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-(甲磺基)吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-(磺酰胺)吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;5-(6-(苄基氨基)-9-((2S,3S,4R,5R)-3,4-二羟基-5-((甲基-d3)-氨苄基)-四氢呋喃-2-基)-9H-嘌呤-2-基)-N-甲基烟酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-苯氧基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-(苄氧基)吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-氟吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-甲氧基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-乙基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-代甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-(甲氧基甲基)吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-羟基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(6-羟基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(1-甲基-1H-吡唑啉[3,4-b]吡啶-5-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(6-(2-甲基-2H-四唑-5-基)吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-(2-甲基-2H-四唑-5-基)吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(吡啶-2-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲胺基)-2-(吡啶-3-基)-9H-嘌呤-9-基)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-N-乙基-5-(2-(5-氟吡啶-3-基)-6-(甲胺基)-9H-嘌呤-9-基)-3,4-二羟基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(1-甲基-1H-咪唑-4-基)-6-(甲基氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(1-甲基-1H-吡咯-3-基)-6-(甲基氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(3-甲基-1H-)吡唑-4-基)-6-(甲基氨基)-9H-嘌呤-9-基)四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(1-甲基-1H-吡咯-2-基)-6-(甲基氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(1,3-二甲基-1H-吡唑-4-基)-6-(甲基氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(1,5-二甲基-1H-吡唑-4-基)-6-(甲氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲基氨基)-2-(噻唑-5-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(3,5-二甲基-1H-吡唑-4-基)-6-(甲氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(1-甲基-3-苯基-1H-吡唑-4-基)-6-(甲基氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(2-氯-1-甲基-1H-咪唑-5-基)-6-(甲基氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(1-甲基-1H-吡唑-4-基)-6-(甲基氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲基氨基)-2-(1,3,5-三甲基-1H-吡唑-4-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(1-甲基-3-(三氟甲基)-1H-吡唑-4-基)-6-(甲基氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(2-甲氧基吡啶-3-基)-6-(甲氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(6-甲氧基吡啶-3-基)-6-(甲氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5,6-二甲氧基吡啶-3-基)-6-(甲氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(4-甲氧基吡啶-3-基)-6-(甲氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(2,6-二甲氧基吡啶-3-基)-6-((甲基-d3)-氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-D3-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-(甲基-d3)-5-(6-((甲基-d3)-氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-乙基吡啶-3-基)-6-((甲基-d3)-氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((甲基-d3)-氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-(甲基-d3)-5-(6-((甲基-d3)-氨基)-2-(5-(三氟甲基)吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-(甲基-d3)-5-(6-((甲基-d3)-氨基)-2-(5-(丙-1-炔-1-基)吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-环丙基吡啶-3-基)-6-((甲基-d3)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(乙氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-甲基-5-(2-(5-甲基吡啶-3-基)-6-((吡啶-2-基甲基)氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(甲氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氟吡啶-3-基)-6-(((4-甲基吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲基氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(5-甲氧基吡啶-3-基)-6-(甲氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-5-(2-(呋喃-3-基)-6-(甲基氨基)-9H-嘌呤-9-基)-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(2,5-二甲基噻吩-3-基)-6-(甲基氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(2-甲氧基苯基)-6-(甲基氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲基氨基)-2-(噻吩-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲基氨基)-2-(噻吩-2-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲基氨基)-2-(4-甲基噻吩-2-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲基氨基)-2-(5-甲基噻吩-2-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-5-(2-(呋喃-2-基)-6-(甲基氨基)-9H-嘌呤-9-基)-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲基氨基)-2-(5-苯基噻吩-2-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲基氨基)-2-(5-邻甲苯基)呋喃-2-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(2-(5-(2-甲氧基苯基)呋喃-2-基)-6-(甲基氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲基氨基)-2-(5-甲基呋喃-2-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(2-氯噻吩-3-基)-6-(甲基氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(2'-氯-(2,3'-联噻吩-3-基)-6-(甲基氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氟吡啶-3-基)-6-(甲氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氰基噻吩-2-基)-6-(甲基氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(甲基氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-N-乙基-3,4-二羟基-5-(6-(甲基氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-((甲基-d3))-5-(6-((甲基-d3)氨基)-2-(噻吩-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(呋喃-2-基)-6-((甲基-d3)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-((甲基-d3))四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-((甲基-d3))-5-(6-((甲基-d3)氨基)-2-(噻吩-2-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氰基吡啶-3-基)-6-((甲基-d3)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-((甲基-d3))-5-(6-((甲基-d3)氨基)-2-(5-苯基吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(呋喃-3-基)-6-((甲基-d3)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-(甲基-d3)-5-(6-((甲基-d3)氨基)-2-(5-(吗啉代甲基)吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-(甲基-d3)-5-(6-((甲基-d3)氨基)-2-(5-(丙-1-炔-1-基)吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺胺;(2S,3S,4R,5R)-5-(2-(5-氟吡啶-3-基)-6-((甲基-d3)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-(甲基-d3)-5-(2-(1-甲基-1H-吡咯-2-基)-6-((甲基-d3)氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-甲基-5-(6-(甲基氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-5-(2-(5-甲氧基吡啶-3-基)-6-(甲氨基)-9H-嘌呤-9-基)-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((3-氯苄基)氨基)-2-(5-氟吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氟吡啶-3-基)-6-((3-甲氧基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氟吡啶-3-基)-6-(((6-甲基吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-甲基-5-(6-(((6-甲基吡啶-2-基)甲基)氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-甲基-5-(6-((3-甲基苄基)氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-苯基-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-5-(2-(5-甲氧基吡啶-3-基)-6-(((6-甲基吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-N-甲基四氢呋喃-2-羧酰胺;((2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(((6-甲基吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(吡啶-4-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-邻甲苯基-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-间甲苯基-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-对甲苯基-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(4-乙基苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(3-甲基吡啶-4-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(6-甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-([[1,1'-联苯]-3-基)-6-(苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(4-(吡啶-3-基)苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-([[1,1'-联苯]-4-基)-6-(苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(2-氯苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(3-氯苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(4-氯苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(2-氟苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(3-氟苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(4-氟苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(4-羟基苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(2-羟基苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(3-羟基苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(2-甲氧基苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(3-甲氧基苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(4-甲氧基苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(2-(三氟甲氧基)苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(3-(三氟甲氧基)苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(4-(三氟甲氧基)苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(4-(2-甲氧基乙氧基)苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(嘧啶-5-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(2,5-二氟苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(3,5-二氟苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(3,4-二氟苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(2,3-二氟苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(4-甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(2-甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(2,6-二甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(3-(甲基氨基)苯基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(呋喃-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(噻吩-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(5-硝基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(5-氟吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(5-(甲基氨基)吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(噻吩-2-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(5-(异丙基氨基)吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(1-甲基-1H-吡咯-2-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(5-乙氧基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((((6-甲氧基吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((3-甲基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氟吡啶-3-基)-6-((3-甲基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氟吡啶-3-基)-6-((3-甲基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(对甲苯基甲烷氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(间甲苯基甲烷氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(4-(三氟甲基)苄基氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-(三氟甲基)苄基氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(4-氟苄基氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(4-氯苄氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-代甲酰胺;(2S,3S,4R,5R)-5-(6-((5-溴吡啶-2-基)甲胺基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-((5-氯吡啶-2-基)甲胺基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((5-甲基吡啶-2-基)甲胺基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((1-甲基-1H-四唑-5-基)甲胺基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((2-甲基-2H-四唑-5-基)甲胺基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-((1H-四唑-5-基)甲胺基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-((1H-1,2,3-三唑-4-基)甲胺基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(2-氯-5-甲基苄基氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(2-氯-5-甲基苄基氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-(三氟甲基)苄基氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-(三氟甲基)苄基氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-(三氟甲基)苄基氨基)-2-(5-氟吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-(三氟甲基)苄基氨基)-2-(5-甲氧基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-((4-氯吡啶-2-基)甲胺基)-2-(吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-((4-氯吡啶-2-基)甲胺基)-2-(5-氟吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-((4-氯吡啶-2-基)甲胺基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-((4-氯吡啶-2-基)甲胺基)-2-(5-甲氧基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-甲基-5-(6-((4-甲基吡啶-2-基)甲胺基)-2-(吡啶-3-基)-9H-嘌呤-9-基)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-(5-甲氧基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-氯苄基氨基)-2-(5-甲氧基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-甲氧基苄基氨基)-2-(5-甲氧基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-甲基-5-(6-((4-甲基吡啶-2-基)甲胺基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(2-氟-5-甲基苄基氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(2-氟-5-甲基苄基氨基)-2-(5-氟吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(2-氟-5-甲基苄基氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(2-氟-5-甲基苄基氨基)-2-(5-甲氧基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((2-(吡啶-2-基)乙基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((四氢-2H-吡喃-4-基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(甲氧基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((2-(吡啶-3-基)乙基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(环戊基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((2-(吡啶-4-基)乙基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((((1-甲基-1H-吡唑-4-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(((2,2,2-三氟乙基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((((1H-吡唑-4-基)甲基)氨基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((((1-甲基-1H-咪唑-5-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(((1-甲基-1H-咪唑-4-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(((1H-咪唑-4-基)甲基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(((1H-吡咯-3-基)甲基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(((1H-吡咯-2-基)甲基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-D3-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((3-氯苄基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((3-氟苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((3-溴苄基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((3-碘苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(2-(5-氯吡啶-3-基)-6-((3-甲氧苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((((4-氯吡啶-2-基)甲基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((((4-甲基吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((((4-(三氟甲基)吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(((4-溴吡啶-2-基)甲基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(6-((3-氯苄基)氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-5-(6-((3-甲氧基苄基)氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((3-甲氧基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((3-氰基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((3-氯-5-甲基苄基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((3-乙基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((3,5-二甲基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((2-氟-5-甲基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((2-氟-5-甲基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(((6-氯吡啶-2-基)甲基)氨基)氨基)-2-(5-氟吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((3-氯苄基)氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-5-(6-((3-甲氧基苄基)氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(((6-氯吡啶-2-基)甲基)氨基)-2-(5-甲氧基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((3,5-二甲基苄基)氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(苯乙基氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(吡啶-2-甲基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(吡啶-4-基甲基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(吡啶-3-基甲基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(3-氯苄基氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(3-碘苄氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(3-氟苄基氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(3-溴苄氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(3,5-二氯苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(3-氯-5-氟苄氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(2,5-二氯苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(3,5-二氟苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(5-氯-2-氟苄氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(2-氯-5-氟苄氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((((6-氯吡啶-2-基)甲基)氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((3-溴苄基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((3-氯苄基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((3-碘苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((((R)-1-苯乙基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((((S)-1-苯乙基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((噻唑-4-基甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((噻吩-2-基甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((噻吩-3-基甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((呋喃-2-基甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((恶唑-4-基甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((呋喃-3-基甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((噻唑-2-基甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(2,2,2-三氟乙基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(3-氟苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(2,2,2-三氟乙基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(3-氯苄氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(2,2,2-三氟乙基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(3-溴苄氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(2,2,2-三氟乙基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(3-碘苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(2,2,2-三氟乙基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(3-甲氧苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(4-溴苄氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(4-甲氧苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(4-碘苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(4-(三氟甲氧基)苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(3-(三氟甲氧基)苄氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((6-甲基吡啶-2-基)甲氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((6-溴吡啶-2-基)甲基氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((6-甲氧基吡啶-2-基)甲氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-((6-氯吡啶-2-基)甲基氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-乙基-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-乙基-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-异丙基-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-异丙基-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-异丙基-9H-嘌呤-9-基)-3,4-二羟基-N-(2,2,2-三氟乙基)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(苄基氨基)-2-异丙基-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-甲基苄基氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(2-(5-乙基吡啶-3-基)-6-((3-甲基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-((3-甲基苄基氨基)-2-(5-乙基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(6-(3-甲基苄基氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基-四氢呋喃-2-甲酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(丙基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(环丁基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(6-氨基-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((2-甲氧基乙基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氟吡啶-3-基)-6-(((6-(三氟甲基)吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(((6-(三氟甲基)吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-5-(2-(5-甲氧基吡啶-3-基)-6-(((6-(三氟甲基)吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-甲基-5-(2-(吡啶-3-基)-6-(((6-(三氟甲基)吡啶-2-基]甲基)氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(((4-甲基吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(((4-(三氟甲基)吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-甲基-5-(6-(((6-甲基吡啶-2-基)甲基)氨基)-2-(5-甲基吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(((4-甲氧基吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(6-((3,5-二甲基苄基)氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(6-((3,5-二甲基苄基)氨基)-2-(5-甲氧基吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(6-((3,5-二甲基苄基)氨基)-2-(5-氟吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-3,4-二羟基-5-(2-(5-甲氧基吡啶-3-基)-6-((3-甲基苄基氨基)-9H-嘌呤-9-基)-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(2-(5-乙氧基吡啶-3-基)-6-((3-甲基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-3,4-二羟基-5-(2-(5-甲氧基吡啶-3-基)-6-((3-甲基苄基氨基)-9H-嘌呤-9-基)-N-甲基-D3-四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(2-(5-乙氧基吡啶-3-基)-6-((3-甲基苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-3,4-二羟基-N-甲基-5-(6-((吡啶-2-基甲基)氨基)-2-(吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(2-(5-氟吡啶-3-基)-6-((吡啶-2-基甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(2-(5-氯吡啶-3-基)-6-((吡啶-2-基甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-3,4-二羟基-5-(2-(5-甲氧基吡啶-3-基)-6-((吡啶-2-基甲基)氨基)-9H-嘌呤-9-基)-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(6-((((6-氯吡啶-2-基)甲基)氨基)-2-(5-氯吡啶-3-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-3,4-二羟基-N-甲基-5-(2-(吡啶-3-基)-6-((((4-(三氟甲基)吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(2-(5-氟吡啶-3-基)-6-((((4-(三氟甲基)吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-3,4-二羟基-5-(2-(5-甲氧基吡啶-3-基)-6-((((4-(三氟甲基)吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-3,4-二羟基-5-(2-(5-甲氧基吡啶-3-基)-6-((((4-甲基吡啶-2-基)甲基)氨基)-9H-嘌呤-9-基)-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-苄基-6-(甲基氨基)-9H-嘌呤-9-基)-N-乙基-3,4-二羟基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-乙氧基吡啶-3-基)-6-(甲氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲氧基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-甲氧基-5-(6-(甲基氨基)-2-(5-(甲基磺酰基)吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-N-甲氧基-5-(6-(甲基氨基)-2-(5-苯氧基吡啶-3-基)-9H-嘌呤-9-基)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-3,4-二羟基-5-(2-(5-异丙氧基吡啶-3-基)-6-(甲氨基)-9H-嘌呤-9-基)-N-甲氧基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-(苄氧基)吡啶-3-基)-6-(甲氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲氧基四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(异丙氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-(环丙基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((3-氟苄基氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-(甲基-d3)-四氢呋喃-2-羧酰胺;(2S,3S,4R,5R)-5-(2-(5-氯吡啶-3-基)-6-((3,4-二氟苄基)氨基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺;(2S,3S,4R,5S)-5-(6-(苄氨基)-2-(吡啶-2-基)-9H-嘌呤-9-基)-3,4-二羟基-N-甲基四氢呋喃-2-羧酰胺。
- 权利要求1-11中任一项所述的化合物或其药学上可接受的盐的溶剂化物、水合物、立体异构体、互变异构体、同位素标记物、代谢物或前药。
- 药物组合物,其包括权利要求1-11中任一项所述的化合物或其药学上可接受的盐,和/或权利要求12所述的溶剂化物、水合物、立体异构体、互变异构体、同位素标记物、代谢物或前药,以及任选地药学上可接受的载体。
- 权利要求1-11中任一项所述的化合物或其药学上可接受的盐,权利要求12所述的溶剂化物、水合物、立体异构体、互变异构体、同位素标记物、代谢物或前药,或权利要求13所述的药物组合物在制备A3腺苷受体激动剂中的应用。
- 权利要求1-11中任一项所述的化合物或其药学上可接受的盐,权利要求12所述的溶剂化物、水合物、立体异构体、互变异构体、同位素标记物、代谢物或前药,或权利要求13所述的药物组合物在制备用于预防和/或治疗A3腺苷受体介导或与A3腺苷受体有关的疾病的药物中的应用。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021413448A AU2021413448A1 (en) | 2020-12-29 | 2021-12-29 | Adenosine a3 receptor agonists, preparation methods and uses thereof |
JP2023540498A JP2024502068A (ja) | 2020-12-29 | 2021-12-29 | A3アデノシン受容体アゴニスト及びその調製方法と用途 |
KR1020237023189A KR20230125800A (ko) | 2020-12-29 | 2021-12-29 | A3 아데노신 수용체 작용제 및 이의 제조 방법과 용도 |
CN202180088308.4A CN116783196A (zh) | 2020-12-29 | 2021-12-29 | A3腺苷受体激动剂及其制备方法和用途 |
CA3203676A CA3203676A1 (en) | 2020-12-29 | 2021-12-29 | Adenosine a3 receptor agonists, preparation methods and uses thereof |
US18/270,117 US20240116975A1 (en) | 2020-12-29 | 2021-12-29 | Adenosine a3 receptor agonists, preparation methods and uses thereof |
EP21914472.2A EP4273153A4 (en) | 2020-12-29 | 2021-12-29 | ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011601817 | 2020-12-29 | ||
CN202011601817.6 | 2020-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022143740A1 true WO2022143740A1 (zh) | 2022-07-07 |
WO2022143740A8 WO2022143740A8 (zh) | 2023-07-13 |
Family
ID=82260231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/142384 WO2022143740A1 (zh) | 2020-12-29 | 2021-12-29 | A3腺苷受体激动剂及其制备方法和用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240116975A1 (zh) |
EP (1) | EP4273153A4 (zh) |
JP (1) | JP2024502068A (zh) |
KR (1) | KR20230125800A (zh) |
CN (1) | CN116783196A (zh) |
AU (1) | AU2021413448A1 (zh) |
CA (1) | CA3203676A1 (zh) |
WO (1) | WO2022143740A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040116376A1 (en) * | 2001-08-08 | 2004-06-17 | Elfatih Elzein | Adenosine A3 receptor agonists |
CN1538972A (zh) * | 2001-08-08 | 2004-10-20 | CVҽҩ����˾ | 腺苷a3受体激动剂 |
US20090156544A1 (en) * | 2005-05-19 | 2009-06-18 | Elfatih Elzein | A1 adenosine receptor agonists |
CN101472925A (zh) * | 2006-04-21 | 2009-07-01 | 诺瓦提斯公司 | 用作腺苷a2a受体激动剂的嘌呤衍生物 |
CN108697719A (zh) * | 2016-01-08 | 2018-10-23 | 艾库斯生物科学有限公司 | 胞外5′-核苷酸酶的调节剂及其用途 |
US20200115404A1 (en) * | 2017-03-31 | 2020-04-16 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
WO2020247546A1 (en) * | 2019-06-03 | 2020-12-10 | Biointervene, Inc. | Adenosine analogs for the treatment of disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995002604A1 (en) * | 1993-07-13 | 1995-01-26 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
AU2002362443B2 (en) * | 2001-10-01 | 2008-05-15 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
EP1469864A1 (en) * | 2002-01-25 | 2004-10-27 | Muscagen Limited | Compounds useful as a-3 adenosine receptor agonists |
WO2008156513A2 (en) * | 2007-03-29 | 2008-12-24 | University Of Connecticut | Methods to protect skeletal muscle against injury |
-
2021
- 2021-12-29 AU AU2021413448A patent/AU2021413448A1/en active Pending
- 2021-12-29 WO PCT/CN2021/142384 patent/WO2022143740A1/zh active Application Filing
- 2021-12-29 EP EP21914472.2A patent/EP4273153A4/en active Pending
- 2021-12-29 KR KR1020237023189A patent/KR20230125800A/ko unknown
- 2021-12-29 US US18/270,117 patent/US20240116975A1/en active Pending
- 2021-12-29 CN CN202180088308.4A patent/CN116783196A/zh active Pending
- 2021-12-29 JP JP2023540498A patent/JP2024502068A/ja active Pending
- 2021-12-29 CA CA3203676A patent/CA3203676A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040116376A1 (en) * | 2001-08-08 | 2004-06-17 | Elfatih Elzein | Adenosine A3 receptor agonists |
CN1538972A (zh) * | 2001-08-08 | 2004-10-20 | CVҽҩ����˾ | 腺苷a3受体激动剂 |
US20090156544A1 (en) * | 2005-05-19 | 2009-06-18 | Elfatih Elzein | A1 adenosine receptor agonists |
CN101472925A (zh) * | 2006-04-21 | 2009-07-01 | 诺瓦提斯公司 | 用作腺苷a2a受体激动剂的嘌呤衍生物 |
CN108697719A (zh) * | 2016-01-08 | 2018-10-23 | 艾库斯生物科学有限公司 | 胞外5′-核苷酸酶的调节剂及其用途 |
US20200115404A1 (en) * | 2017-03-31 | 2020-04-16 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
WO2020247546A1 (en) * | 2019-06-03 | 2020-12-10 | Biointervene, Inc. | Adenosine analogs for the treatment of disease |
Non-Patent Citations (11)
Title |
---|
BAR-YEHUDA ET AL., ARTHRITIS RHEUM, vol. 60, 2009, pages 3061 - 3071 |
BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104 |
COSYN, LIESBET; PALANIAPPAN, KRISHNAN K.; KIM, SOO-KYUNG; DUONG, HENG T.; GAO, ZHAN-GUO; JACOBSON, KENNETH A.; VAN CALENBERGH, SER: "2-Triazole-Substituted Adenosines: A New Class of Selective A3 Adenosine Receptor Agonists, Partial Agonists, and Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 49, no. 25, 14 December 2006 (2006-12-14), US , pages 7373 - 7383, XP009132900, ISSN: 0022-2623, DOI: 10.1021/jm0608208 * |
GESSI ET AL., CLIN. CANCER RES., vol. 210, 2004, pages 4472 - 4479 |
JACOBSON ET AL., PAIN, vol. 161, 2020, pages 1425 - 1441 |
MULLOY ET AL., ANN. THORAC. SURG., vol. 95, no. 5, 2013, pages 1762 - 7 |
OCHAION ET AL., CELL. IMMUNOL., vol. 258, 2009, pages 115 - 122 |
REN TIANHUA ET AL., INTERNATIONAL JOURNAL OF DIGESTIVE DISEASES, vol. 38, no. 6, 2018, pages 407 - 412 |
See also references of EP4273153A4 |
WANGJUNLI ET AL., MEDICAL RECAPITULATE, vol. 14, no. 12, 2008, pages 3585 - 3587 |
XIONG HONGYAN ET AL., J. CHINESE JOURNAL OF EXTRACORPOREAL CIRCULATION, vol. 14, no. 3, 2016, pages 172 - 176 |
Also Published As
Publication number | Publication date |
---|---|
WO2022143740A8 (zh) | 2023-07-13 |
CN116783196A (zh) | 2023-09-19 |
EP4273153A1 (en) | 2023-11-08 |
CA3203676A1 (en) | 2022-07-07 |
KR20230125800A (ko) | 2023-08-29 |
JP2024502068A (ja) | 2024-01-17 |
AU2021413448A1 (en) | 2023-07-20 |
EP4273153A4 (en) | 2024-05-08 |
US20240116975A1 (en) | 2024-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3280715B1 (en) | NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | |
EP3707138B1 (en) | Isofuranone compounds useful as hpk1 inhibitors | |
CN109071498B (zh) | 激酶抑制剂及其制备方法和用途 | |
US9206175B2 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
TW202144345A (zh) | Kras突變蛋白抑制劑 | |
CN109232440B (zh) | 用于抑制激酶活性的二苯氨基嘧啶类化合物 | |
EP2498780B1 (en) | N-9-substituted purine compounds, compositions and methods of use | |
CN102459300A (zh) | 用于治疗用途的新的7-脱氮嘌呤核苷 | |
JP2010522209A (ja) | PI3キナーゼおよびmTORの阻害剤としてのイミダゾロピリミジン類似体およびその使用 | |
CN101977923A (zh) | 新的抑制细胞生长的7-脱氮嘌呤核苷 | |
WO2019101188A1 (en) | Novel benzoimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenases | |
TWI598348B (zh) | 雜環化合物及其用途 | |
CN111560012A (zh) | 一种作为irak抑制剂的化合物 | |
TW202010500A (zh) | 作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物 | |
TW202317526A (zh) | 用於治療癌症之方法 | |
WO2023125707A1 (zh) | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 | |
JP2020531574A (ja) | 化合物、その医薬組成物及びその使用及び応用 | |
CN109776544B (zh) | 吡唑并[3,4-d]嘧啶类化合物及其制备方法和用途 | |
WO2017071636A1 (zh) | 酞嗪酮衍生物、其制备方法及用途 | |
WO2020259703A1 (zh) | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 | |
CN104822658A (zh) | 作为多种激酶抑制剂的稠合三环酰胺类化合物 | |
WO2020232401A1 (en) | Combination therapies with ire1 small molecule inhibitors | |
CN113366008A (zh) | 一种cd73抑制剂,其制备方法和应用 | |
WO2022143740A1 (zh) | A3腺苷受体激动剂及其制备方法和用途 | |
TWI633107B (zh) | 作為parp抑制劑的稠合四或五環二氫二氮呯并咔唑酮 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21914472 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3203676 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023540498 Country of ref document: JP Ref document number: 202180088308.4 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 20237023189 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021413448 Country of ref document: AU Date of ref document: 20211229 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021914472 Country of ref document: EP Effective date: 20230731 |